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THE 340B PROGRAM: A FEDERAL
PROGRAM IN DESPERATE NEED OF
REVISION AFTER TWO-AND-A-HALF
DECADES OF UNCERTAINTY
NICHOLAS C. FISHER
I. INTRODUCTION
For individuals with limited means, the exponential growth in
pharmaceutical drug prices continues to be a common barrier in accessing lifesaving prescription drugs. Although few people outside the health care and drug
industry are familiar with the 340B Drug Pricing Program (340B Program), the
program plays an integral role in how millions of Americans obtain prescription
drugs.1 The intent of the 340B Program is to help uninsured, indigent patients by
giving qualifying health care facilities access to discounts for outpatient drugs.2
However, after nearly two-and-a-half decades since its inception, it is debatable
whether the program operates in accordance with its statutory foundation.3
Specifically, competing incentives between drug manufacturers and qualifying
health care facilities, the lack of Congressional oversight, and vague language in
the statute and regulations have turned this well-intended program into a revenue
generating arrangement.4
The 340B Program is a federally facilitated program that imposes ceilings
on prices drug manufacturers may charge for certain medications sold to
qualifying health care facilities known as covered entities.5 All drug
manufacturers that supply outpatient drugs are eligible to participate in the 340B

© 2019 Nicholas C. Fisher.
*The author is an Associate Attorney at Hunt Suedhoff Kalamaros. Prior to law school, the
author spent nearly a decade working in retail and hospital pharmacies. The author is grateful to the
Journal of Health Care Law & Policy for selecting this article and to Kristy, Samuel, and Benjamin for
their unconditional love and support.
1. See discussion infra Section III.A.
2. See discussion infra Sections II.A, II.B.
3. See H.R. REP. NO. 102-384, pt. 2, at 12 (1992) (explaining that the program “provides protection
from drug price increases to specified Federally-funded clinics and public hospitals that provide direct
clinical care to large numbers of uninsured Americans.”); see also discussion infra Part III.
4. See discussion infra Part IV.
5. See discussion infra Sections II.B, II.C.
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Program.6 Moreover, drug manufacturers that desire to be reimbursed by
Medicaid must participate in the program.7
The 340B Program has grown substantially since its inception in 1992—
most notably since its expansion under the Patient Protection and Affordable
Care Act in 2010.8 To illustrate the expansion, consider the following: the
number of hospitals participating in the program grew from 591 to 1,673 between
2005 to 2011;9 the number of hospital and affiliated sites grew from 1,233 to
4,426;10 and in “July 2011, there were more than 16,500 covered entity sites
enrolled in the 340B Program—about double the number in 2001.”11
The 340B Program continues to grow at exponential rates. In 2013 alone,
“covered entities and their affiliated sites spent over $7 billion to purchase 340B
drugs, three times the amount spent in 2005.”12 In 2015, discounted purchases
made under 340B hit $12 billion.13 A December 2016 report estimates the
program will reach $20 billion in sales by 2019 and top $23 billion in sales by
2021.14
Still, not everyone is convinced the 340B Program is being used for its
original intentions. In theory, covered entities are supposed to buy the heavily
discounted drugs and pass along the savings to their low-income patients.
However, the 340B statute does not expressly tie patient eligibility to insurance
status nor does it restrict how covered entities use revenue from the 340B
Program. Critics of the program point out that hospitals with low numbers of
indigent patients use the program to obtain drugs for outpatients who have
Medicare or private insurance. In cases where insured patients are treated with
6. See discussion infra Section II.B.
7. See discussion infra Section II.B.
8. 42 U.S.C. § 256b (2012).
9. U.S. GOV’T ACCOUNTABILITY OFF., GAO-11-836, DRUG PRICING: MANUFACTURER DISCOUNTS
IN THE 340B PROGRAM OFFER BENEFITS, BUT FEDERAL OVERSIGHT NEEDS IMPROVEMENT 27–28 (2011),
http://www.gao.gov/assets/330/323702.pdf [hereinafter GAO, DRUG PRICING]. The GAO, Government
Accountability Office, “is an independent, nonpartisan agency that works for Congress. Often called the
‘congressional watchdog,’ the GAO investigates how the federal government spends taxpayer dollars.”
U.S. Gov’t Accountability Off., About GAO, GAO.GOV (last visited Oct. 28, 2018),
https://www.gao.gov/about/index.html.
10. Id. at 27–28.
11. Id. at 2–3.
12. MEDICARE PAYMENT ADVISORY COMM’N, REPORT TO THE CONGRESS: OVERVIEW OF THE 340B
DRUG PRICING PROGRAM 11 (MedPAC ed. 2015) [hereinafter MEDPAC: DRUG PRICING]. The Medicare
Payment Advisory Commission (MedPAC) “is a nonpartisan legislative branch agency that provides the
U.S. Congress with analysis and policy advice on the Medicare program.” MEDICARE PAYMENT
ADVISORY COMMISSION, http://www.medpac.gov/ (last visited Oct. 28, 2018).
13. Adam J. Fein, 340B Purchases Hit $12 Billion in 2015—and Almost Half of the Hospital Market,
DRUG CHANNELS (Feb. 23, 2016), http://www.drugchannels.net/2016/02/340b-purchases-hit-12-billionin.html.
14. AARON VANDERVELDE & ELEANOR BLALOCK, BRG HEALTHCARE, 340B PROGRAM SALES
FORECAST: 2016-2021, 2 (Berkeley Research Group ed. 2016), https://www.thinkbrg.com/media/
publication/855_Vandervelde_Blalock_340B_Dec2016_WEB.pdf.
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discounted drugs, the hospital is routinely reimbursed for the full price of the
drug by the federal government or private insurance and the entity retains the
difference. Critics argue that this is the antithesis of the 340B Program—a
program designed to help impoverished patients with limited means. Meanwhile,
advocates argue that qualifying providers are able to expand the type and volume
of care they provide to the most vulnerable patient populations as a result of
access to these lower cost medications.
Issues with the 340B Program stem from the lack of guidance. The law is
inundated with vagueness and ambiguities. For example, the law requires that
covered entities only use 340B drugs for individuals who are patients of the
covered entity. However, the statute does not define the term “patient” due to the
large number of covered entities and the wide diversity of eligible groups. In
2011, the U.S. Government Accountability Office (GAO) deemed the term was
“not specific enough” and could be interpreted “either too broadly or too
narrowly.”15 Despite the need for clarity and the call for an updated definition,
there has yet to be a final update of the definition in over 20 years.
Fueling the fire, the Health Resources and Services Administration
(HRSA)—the agency responsible for administering the program—has relied
heavily on self-policing.16 Despite having the authority to conduct audits, a 2011
report found that HRSA had not conducted a single audit since the program’s
inception in 1992.17 Meanwhile, drug manufacturers and covered entities
continue to rely on their own interpretations of the law due to the lack of clear
guidelines. As a result, both covered entities and drug manufacturers are
incentivized to interpret the law in accordance with their respective interests.
Furthermore, in 2014, the D.C. Circuit held that HRSA—the federal agency
vested with the responsibility to oversee and enforce the 340B Program—lacks
broad rulemaking authority for the program.18 Prior to the ruling, HRSA used
“interpretive guidance and statements of policy to provide guidance” to program
participants.19 However, the court found that Congress had delegated only very
limited rulemaking authority to HRSA. This ruling left HRSA’s rulemaking
authority on shaky grounds and opened the door for additional legal challenges
with a template to succeed.
The original intent of the program was to help lower outpatient drug prices
for the uninsured. Due to inadequate oversight and lack of necessary direction,

15. GAO, DRUG PRICING, supra note 9, at 22.
16. GAO, DRUG PRICING, supra note 9, at 21.
17. GAO, DRUG PRICING, supra note 9, at 25.
18. Pharm. Research & Mfrs. of Am. v. U.S. Dep’t of Health & Human Serv. (PhRMA I), 43 F. Supp.
3d 28, 39 (D.D.C. 2014); Pharm. Research & Mfrs. of Am. v. U.S. Dept. of Health & Human Serv.
(PhRMA II), 138 F. Supp. 3d 31, 48 (D.D.C. 2015).
19. Notice Regarding 340B Drug Pricing Program—Contract Pharmacy Services, 75 Fed. Reg.
10,272, 10,273 (Mar. 5, 2010).
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both drug manufacturers and qualifying health care providers have run amok.
The 340B Program faces several internal challenges due to its nuanced and
cumbersome nature. Furthermore, there is rarely a simple solution for a complex
problem. However, this paper proposes by updating a few key areas, not only
would program participants have better guidance, but the program’s original
intent would be preserved.
A. Roadmap
This paper is divided into three parts. First, this paper tracks the history of
the 340B Program. This section provides a comprehensive history and overview
of the program by focusing on the program’s configuration, the compliance
requirements for covered entities and drug manufacturers, and the underpinnings
of regulatory guidance. Second, this paper examines the 340B Program’s
explosive growth and rapid expansion under the Affordable Care Act and
evaluates how increased growth has brought increased scrutiny. This section
tracks the legal clashes between HHS and PhRMA over the orphan drug rule, and
evaluates the standards used by the courts to determine that HHS has limited
authority to issue binding guidance over the program. Additionally, this section
provides a look at how these rulings undermine the administrative function of
HRSA and how the success of PhRMA threatens the stability of the 340B
Program by providing a roadmap for future challenges. The final section of this
paper addresses five key areas of the program that, if updated, would help the
program find its intended purpose—helping the indigent. This last section
analyzes the program’s lack of transparency, how ambiguities have crippled the
program, and how the intrinsic nature of the program has locked drug
manufacturers and covered entities into a zero-sum game. Moreover, this section
also discusses how the failure of the federal government to amend the law
undermines HRSA’s ability to properly administer the program. This paper
concludes that without congressional action and key updates, the 340B Program
will remain in disarray.
II. HISTORY OF THE 340B DRUG PRICING PROGRAM
A. Medicaid Drug Rebate Program
The 340B Program is intrinsically tied to the Medicaid Drug Rebate
Program. In 1990, Congress created the Medicaid Drug Rebate Program
(MDRP) to help offset the costs of prescription drugs for Medicaid patients.20
The program was enacted out of concern for the costs the Medicaid program was
paying for outpatient drugs. The intent of the program was to restrain drug price
20. Omnibus Budget Reconciliation Act of 1990, Pub. L. No. 101-508, §4401, 104 Stat. 1388, 1388143 (codified as amended at 42 U.S.C. § 1395ww (2012)).
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increases for state Medicaid programs.21 Under the MDRP, drug manufacturers
are required to enter into a rebate agreement with the Secretary of the U.S.
Department of Health and Human Services in exchange for Medicaid coverage
of the manufacturer’s drugs.22
The MDRP works by acting as an opt-in mechanism that affords state
Medicaid programs the opportunity to reimburse pharmacies for drugs at
discounted prices similar to those offered by drug manufacturers to other
purchasers.23 State Medicaid agencies submit requests for reimbursement to drug
manufacturers for outpatient prescription drugs dispensed to Medicaid
beneficiaries.24 The drug manufacturer issues a rebate to the state Medicaid
agency reflecting the discount from the full price of outpatient drugs to Medicaid
beneficiaries.25 In sum, the program requires drug manufacturers to offer state
Medicaid programs discounts on outpatient drugs that would at least match the
lowest price the drug is offered to other purchasers.26
The drug manufacturers pay rebates that are determined by a formula that
is based on a manufacturer’s Average Manufacturer Price (AMP) and “best”
price.27 Both the AMP and best price are defined by legislation and regulation.28
The MDRP was designed to help lower Medicaid spending on outpatient
prescription drugs by ensuring states receive discounts similar to those provided
to private purchasers.
i. Prior to 1990 Medicaid Drug Rebate Program (MDRP)
Prior to the MDRP, drug manufactures regularly offered discounts to the
Department of Veteran Affairs hospitals and other safety-net providers serving
the uninsured and indigent population.29 The MDRP required the manufacturers
21. S. REP. NO. 102-259, at 6 (1992).
22. Id. at 6; 42 U.S.C. § 1396r-8 (2012); Medicaid Drug Rebate Program, MEDICAID.GOV,
https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html (last
updated Sept. 11, 2011).
23. § 4401, 104 Stat. 1388-143.
24. Id.
25. Id.
26. S. REP. NO.102-259, at 6.
27. 42 U.S.C. § 1396r-8(c)(1)(A)(ii) (2012).
28. The term “average manufacturer price” means the average price paid to the manufacturer for the
drug by (i) wholesalers for drugs distributed to retail community pharmacies; and (ii) retail community
pharmacies that purchase drugs directly from the manufacturer. Id. § 1396r-8(k)(1)(A). The best price is
the lowest price available from the manufacturer during the rebate period to any wholesaler, retailer,
provider, HMO, nonprofit entity, or government entity, excluding prices charged to certain federal
programs, 340B covered entities, Medicare Part D plans, and certain other purchasers. Id. § 1396r8(c)(1)(C); Medicaid Program; Covered Outpatient Drugs, 81 Fed. Reg. 5170, 5351 (Feb. 1, 2016) (to be
codified at 42 C.F.R. pt. 447).
29. Connor J. Baer, Drugs for the Indigent: A Proposal to Revise the 340B Drug Pricing Program,
57
WM.
&
MARY
L.
REV.
637,
641
(2015),
http://scholarship.law.wm.edu/cgi/viewcontent.cgi?article=3623&context=wmlr. A safety-net provider is

30

JOURNAL OF HEALTH CARE LAW & POLICY

[VOL. 22:25

to provide rebates to Medicaid for the lowest price they offered in the rest of the
drug marketplace.30 However, the MDRP failed to exempt these discounts from
the Medicaid best price provision.31 After MDRP, drug manufacturers were
disincentivized to continue giving discounts on drugs because the discounts
would establish lower AMPs and best prices which would require drug
manufacturers to pay larger rebates to Medicaid.32 As a result, there was an
increase in drug costs.33 In reaction to this unintended consequence from the
MDRP, Congress created the 340B Drug Pricing Program to help the federal
government and safety-net hospitals avoid financial hardships and to ensure that
the uninsured and underinsured had access to prescription medicines.34
B. 340B Drug Pricing Program
In 1992, Congress created the 340B Drug Pricing Program.35 Enacted under
the Veterans Health Care Act of 1992,36 the program’s name is derived from the
provision in the Public Health Service Act that authorizes it.37 The 340B Program
is administered by the Office of Pharmacy Affairs (OPA), located within the
Health Resources and Services Administration (HRSA), under the U.S.
Department of Health and Human Services (HHS).38 The intent of the 340B
Program is to permit covered entities “to stretch scarce Federal resources as far
as possible, reaching more eligible patients and providing more comprehensive
services.”39

a hospital or health system that provides a significant level of health care and related services to lowincome, uninsured, and vulnerable populations. Dave A. Chokshi, MD, MSc, FACP, et al., Health Reform
and the Changing Safety Net in the United States, NEJM CATALYST (Oct. 18 2017),
https://catalyst.nejm.org/health-reform-changing-safety-net/.
30. ACAD. OF MANAGED CARE PHARMACY, THE BEST PRICE REQUIREMENT OF THE MEDICAID
REBATE PROGRAM (2009), http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=18692.
31. Id.
32. Overview of the 340B Drug Pricing Program, 340B HEALTH, https://www.340bhealth.org/340bresources/340b-program/overview/ (last visited Oct. 28, 2018) (detailing the Medicaid drug rebate
program 340B).
33. U.S. GOV’T ACCOUNTABILITY OFF., GAO/HRD-91-139, MEDICAID: CHANGES IN DRUG PRICES
PAID BY VA AND DOD SINCE ENACTMENT OF REBATE PROVISIONS 1-2 (1991), https://www.gao.gov/
assets/220/214927.pdf.
34. See supra note 32.
35. See supra note 32.
36. Veterans Health Care Act of 1992, Pub. L. No. 102-585, §§ 601–603, 106 Stat. 4943, 4962–75
(1992) (codified as amended at 42 U.S.C. § 256b (2015)).
37. See 42 U.S.C. § 256b (2012) (establishing that the Veterans Health Care Act of 1992 enacted
section 340B of the Public Health Service Act “Limitation on Prices of Drugs Purchased by Covered
Entities”).
38. See supra note 32.
39. H.R. REP. NO. 102-384, pt. 2, at 12 (1992).
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Eligibility for the 340B Program is defined by statute.40 The program
mandates discounts to qualifying health care providers serving indigent
patients.41 Under the 340B Program, qualifying hospitals and other health care
providers, known as covered entities, can obtain discounted prices on covered
outpatient drugs from drug manufacturers.42 The 340B Program, like the MDRP,
requires drug manufacturers to enter into a contract with the Secretary of HHS,
called pharmaceutical pricing agreements (PPAs).43 Under these agreements, the
manufacturer of must agree to comply with 340B requirements—provide
discounts to covered entities on covered outpatient drugs.44
Participation in the 340B Program is voluntary for both covered entities and
drug manufacturers. However, both have strong incentives to participate.
Qualifying covered entities “can realize substantial savings through 340B price
discounts—an estimated 20 to 50 percent off the cost of drugs, according to
HRSA.”45 Drug manufacturers must participate in the 340B Program in order to
receive Medicaid reimbursement. Manufacturers participating in the 340B
Program are required to provide these discounts on all covered outpatient drugs
sold to participating 340B covered entities.46
The 340B qualifying entities are allowed to buy drugs from drug
manufacturers who agree to a ceiling price for covered drugs. The ceiling price
is derived from manufacturer’s average and best price and rebates calculated
under the MDRP.47 HRSA calculates a 340B ceiling price for each covered
outpatient drug, which represents the maximum price a manufacturer can charge
a covered entity for the drug. The 340B Program is intended to set a standard
price, the ceiling price, to prevent drug manufacturers from charging arbitrarily
high prices.

40. See 42 U.S.C. § 256(b)(4) (establishing that covered entities includes a variety of health programs
receiving federal funding or grants).
41. Id. § 256b(a)(4)(L). Although the qualifications for covered entities has expanded since the
program’s inception, under the original 340B statute, covered entities were generally disproportionate
share hospitals—hospitals that serve indigent populations. Id.; see also Criteria for Hospital Participation
in the 340B Drug Discount Program, 340B HEALTH, https://www.340bhealth.org/340b-resources/340bprogram/criteria-for-hospital-participation/ (last visited Sept. 30, 2018) (explaining qualifications for
hospitals to be deemed covered entities under 340B).
42. 42 U.S.C. § 256b(a)(1); see also 42 U.S.C. § 1396r-8(a)(1) (requiring that qualifying hospitals
and health care providers enter into Agreements with the Secretary to obtain discounts).
43. 42 U.S.C. § 256b(a)(1).
44. 42 U.S.C. § 1396r-8(a)(5). In 2003, Congress required manufacturers of drugs covered under
Medicare Part B to enter into agreements through § 303(i)(4) of the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, 117 Stat. 2066, 2237 (codified as
amended at 42 U.S.C. 1395w-4).
45. GAO, DRUG PRICING, supra note 9, at 2.
46. 42 U.S.C. §256b(a)(1).
47. Id.; 42 U.S.C. 1396r-8(c), (k); Astra USA, Inc. v. Santa Clara Cty., Cal., 563 U.S. 110, 114–15
(2011).
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C. How the 340B Program Works
i. Covered Entities
To be eligible for the 340B discounted prices, a covered outpatient drug
must be provided to a patient of a covered entity.48 Eligibility for the 340B
Program is defined by statute.49 Approved entities must register with HRSA, be
approved by the agency, and follow program requirements. Once enrolled,
covered entities are assigned an identification number that vendors must verify
before an organization is allowed to purchase discounted drugs. Covered entities
must recertify with HRSA through the OPA 340B database website annually. 50
Failure will result in removal from the 340B Program.51
The definition of covered entities includes six types of hospitals:
disproportionate share hospitals (DSH); children’s hospitals and cancer hospitals
exempt from the Medicare prospective payment system; sole community
hospitals; rural referral centers; and critical access hospitals.52 The 340B law has
different eligibility requirements for each of the six types of hospitals. In
addition, a qualified provider may have multiple sites that participate in the
program as long as each site is registered with HRSA, and is an “integral” part
of the covered entity—i.e. the facility is identified as reimbursable on the
hospital’s Medicaid cost report.53
Under the original 340B statute, eligible hospitals included only DSHs.54
Children’s hospitals were added into the program in 2005,55 but did not become
eligible to enroll until 2009 when HRSA issued a guidance.56 In 2010, the Patient
Protection and Affordable Care Act (ACA) expanded the types of covered
entities to include children’s hospitals, free-standing cancer hospitals, critical
access hospitals, rural referral centers, and sole community hospitals.57

48. 42 U.S.C. §§ 256b(a)(4)(A)–(O).
49. Id. § 256b(a)(1).
50. Annual Recertification, HEALTH RES. & SERVS. ADMIN., https://www.hrsa.gov/opa/
recertification/recertification.html (last updated Sept. 2017).
51. Id.
52. 42 U.S.C. § 256b(a)(4).
53. Notice Regarding Section 602 of the Veteran Health Care Act of 1992 Outpatient Hospital
Facilities, 59 Fed. Reg. 47,884, 47,886 (Sept. 19, 1994).
54. Veterans Health Care Act of 1992, Pub. L. No. 102-585 § 602, 106 Stat. 4943, 4968 (1992)
(codified as amended at 42 U.S.C. 256b).
55. Deficit Reduction Act of 2005, Pub. L. No. 109-171 § 6004 120 Stat. 4, 61 (2015) (codified as
amended 42 U.S.C. 1396r-8 (2012)).
56. See Notice Regarding the 340B Drug Pricing Program—Children’s Hospitals, 74 Fed. Reg.
45,206, 45,206 (Sept. 1, 2009) (describing the process for registration in 2009 and the obligation of
manufacturers to provide discounts to eligible children’s hospitals).
57. Patient Protection and Affordable Care Act, Pub. L. 111-148, § 7101(a), 124 Stat. 119, 821–22
(2010) (codified as amended at 42 U.S.C. §§ 256b(a)(4)(M)–(O) (2012)); PhRMA II, 138 F. Supp. 3d 31,
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Regardless of type of hospital, all 340B hospitals must meet three requirements
with the exception of rural hospitals.58 The first requirement mandates that the
qualifying hospital is owned or operated by a unit of State or local government,
is a public or private non-profit corporation which is formally granted
governmental powers by a unit of State or local government, or is a private nonprofit hospital which has a contract with a State or local government to provide
health care services to low income individuals who are not entitled to benefits
under Title XVIII of the Social Security Act.59 The second requirement is that
the hospital have a sufficient Medicare disproportionate share hospital
adjustment percentage for the most recent cost reporting period that ended before
the calendar quarter involved.60 The third requirement is that a DSH, children’s
hospital, or freestanding cancer hospital enters into a written certification stating
that the entity will not obtain covered outpatient drugs through a group
purchasing organization (GPO)61 or other group purchasing arrangement.62
In addition to the six types of hospitals discussed, there are also eleven
categories of non-hospital covered entities that are eligible for the 340B Program
based on receiving federal funding, such as a grant, or meeting certain
government requirements in providing care to the medically underserved.63 A
full list of eligible organizations/covered entities includes: Federally Qualified
Health Centers (FQHCs); Federally Qualified Health Center “Look-Alikes”;
Native Hawaiian Health Centers; Tribal / Urban Indian Health Centers; Ryan
White HIV/AIDS Program Grantees; Black Lung Clinics; Comprehensive
Hemophilia Diagnostic Treatment Centers; Title X Family Planning Clinics;
Sexually Transmitted Disease Clinics; and Tuberculosis Clinics.64
35 (2012). Children’s hospitals were previously included under the DRA, supra note 55, however the
ACA clarified eligibility.
58. See 42 U.S.C. § 256b(a)(4)(L) (describing three requirements pertaining to hospital ownership,
disproportionate share adjustment percentages, and group purchasing organizations). Rural hospitals must
only meet two requirements. See id. § 256(a)(4)(O) (“An entity that is a rural referral center, as defined
by section 1886(d)(5)(C)(i) of the Social Security Act [42 U.S.C. 1395ww(d)(5)(C)(i)] . . . and that both
meets the requirements of subparagraph (L)(i) and has a disproportionate share adjustment percentage
equal to or greater than 8 percent.”).
59. Id. § 256(a)(4)(L)(i).
60. See id. § 256b(a)(4)(L)(ii) (explaining that the hospital must have had a disproportionate share
adjustment percentage that was “greater than 11.75 percent or was described in section
1886(d)(5)(F)(i)(II) of . . . ” the Social Security Act).
61. See id. § 256b(a)(4)(L)(iii) (describing how a subsection (d) hospital meets the definition of a
covered entity, if among other requirements, it “does not obtain covered outpatient drugs through a group
purchasing organization or other group purchasing arrangement”). A group purchasing organization
(GPO) is an organization “created to leverage the collective [purchasing] power of…entities[] to obtain
discounts from vendors” based on the collective buying power of the GPO members.” GEORGE B.
MOSELEY III, MANAGING LEGAL COMPLIANCE IN THE HEALTH CARE INDUSTRY 100 (2013).
62. 42 U.S.C. § 256b(a)(4)(L)(iii).
63. See id. § 256b(a)(4) (listing the different types of hospitals and non-hospital entities which are
considered covered entities).
64. 42 U.S.C. § 1396d(l)(1)(B).
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a. DSH Adjustment Percentage
All hospitals participating in 340B must have a minimum disproportionate
share adjustment percentage with the exception of critical access hospitals.65
Disproportionate share hospitals serve a significantly disproportionate number
of low-income patients and receive payments from the Centers for Medicaid and
Medicare Services (CMS)66 to cover the costs of providing care to uninsured
patients.67 To qualify for the 340B Program, DSHs must have a DSH adjustment
percentage greater than 11.75 and meet other criteria; sole community hospitals
and rural referral centers must have an adjustment percentage of greater than 8
percent.68
Critical access hospitals are not required to have a minimum DSH
adjustment percentage. Both free-standing children’s hospitals and cancer
hospitals do not receive DSH adjustment payments, however, these hospitals
must have a payer-mix that is greater than a DSH percentage of 11.75 percent.
Outpatient sites affiliated with a hospital do not affect the hospital’s DSH
adjustment percentage because the percentage is based on a hospital’s mix of
inpatients. If a 340B hospital’s DSH adjustment percentage falls below the
minimum, then the hospital is required to inform HRSA—through the OPA—
and the program will be terminated.69
The DSH adjustment percentage was implemented in 1986 as part of the
Medicare program so that hospitals with substantial low-income patient loads
could receive higher payments to cover the higher costs of treating low-income
patients.70 “The DSH adjustment percentage is based on the DSH patient
percentage which equals the sum of the percentage of Medicare inpatient days
attributable to patients eligible for both Medicare Part A and Supplemental
Security Income (SSI), and the percentage of total inpatient days attributable to

65. 340B Drug Pricing Program Omnibus Guidance, 80 Fed. Reg. 52,300, 52,300–02 (Aug. 28,
2015); see also 42 U.S.C. § 256b(a)(4)(L)(i) (describing another type of hospital that is a covered entity
under the Public Health Service Act).
66. Disproportionate Share Hospitals, HEALTH RES. & SERVS. ADMIN., https://www.hrsa.gov/
opa/eligibility-andregistration/hospitals/disproportionate-share-hospitals/index.html (last updated Sept.
2017).
67. Id. (“Disproportionate share hospitals are defined in Section 1886(d)(1)(B) of the Social Security
Act.”).
68. 42 U.S.C. § 256b(a)(4)(L), (O).
69. MEDPAC, supra note 12, at 5.
70. See MEDICARE PAYMENT ADVISORY COMMISSION, REPORT TO THE CONGRESS: MEDICARE
PAYMENT POLICY 70 (MedPAC ed. 2007) [hereinafter MEDPAC: MEDICARE PAYMENT POLICY]
(discussing the implementation date of the DSH adjustment program and the purpose of the program);
Consolidated Omnibus Budget Reconciliation Act of 1985, Pub. L. No. 99-272 § 9105, 100 Stat. 82, 158–
59 (1986) (codified as amended at 42 U.S.C. 1395ww(d)(5)).
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patients eligible for Medicaid but not Medicare Part A.”71 The DSH Percentage
is calculated using the following formula:72
(Medicaid, Non-Medicare Days / Total Patient Days (All Payers))
+ (Medicare SSI Days / Total Medicare Days)
= DSH Percentage
Although the DSH adjustment percentage is the primary method of
demonstrating that a hospital serves a disproportionate share of low-income
patients, there is an exception to the 11.75 percent requirement that applies to
large urban hospitals having 100 beds or more.73 These hospitals must
demonstrate that more than 30 percent of their total net inpatient care revenue
comes from state and local government programs for indigent care other than
Medicare or Medicaid.74
The DSH adjustment percentage is based on the number of Medicaid and
low-income Medicare patients treated on an inpatient basis.75 However, the DSH
formula does not account for uninsured patients.76 In other words, a hospital
could have a number of uninsured patients transitioning to Medicaid which
would make the hospital more likely to qualify for 340B while simultaneously
reducing the burden of uninsured care.77 Critics of 340B take issue with the DSH
metric as a proxy for eligibility because it fails to ensure the program is
benefiting true safety-net hospitals that serve high numbers of indigent patients.78

71. Disproportionate Share Hospital (DSH), The Medicare DSH Adjustment (42 C.F.R. 412.106),
CTRS. FOR MEDICARE & MEDICAID SERVS., https://www.cms.gov/Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/dsh.html (last modified Mar. 19, 2018).
72. Id.; see also 42 C.F.R. § 412.106(b) (2017).
73. U.S. GOV’T ACCOUNTABILITY OFF., GAO-15-442, MEDICARE PART B DRUGS: ACTION NEEDED
TO REDUCE FINANCIAL INCENTIVES TO PRESCRIBE 340B DRUGS AT PARTICIPATING HOSPITALS 4, n.10
(2015), https://www.gao.gov/assets/680/670676.pdf.
74. 42 U.S.C. § 1395ww(d)(v)(F)(i)(II) (2012). These hospitals are known as “Pickle” hospitals—
named for JJ Pickle, a former member of Congress. See 340B Drug Pricing Program, FAQs, HEALTH
RES. & SERVS. ADMIN., https://www.hrsa.gov/opa/faqs/ (last updated Sept. 2018) (stating that “The
11.75% requirement is waived for a few hospitals known as ‘Pickle’ hospitals . . . . “).
75. Medicare Learning Network Fact Sheet, Medicare Disproportionate Share Hospital, CTRS. FOR
MEDICARE & MEDICAID SERVS. (Sept. 2017), https://www.cms.gov/Outreach-and-Education/MedicareLearning-Network.MLN/MLNProducts/downloads/Disproportionate_Share_Hospital.pdf.
76. Karyn Schwartz, 340B Paradox: As the Uninsured Rate Drops, 340B Program Continues to
Grow, PHARM. RESEARCH & MFRS. OF AM. (Apr. 2, 2015) https://catalyst.phrma. org/340b-paradox-asthe-uninsured-rate-drops-340b-program-continues-to-grow.
77. Id.
78. See id. (explaining that as the amount of uncompensated health care provided by hospitals
continues to decrease, a greater number of facilities will qualify for the 340B program which critics argue
will lead to the program’s “uncontrolled and unsustainable growth”).
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b. Contract Pharmacies
Although the 340B statute does not explicitly mention contract pharmacies,
“covered entities are free to choose how they provide 340B pharmacy services
to their patients, subject to state and federal laws.”79 Many covered entities
provide 340B drugs through an in-house pharmacy.80 However, 340B covered
entities may contract with a pharmacy or pharmacies that are not part of the entity
to provide services to the covered entity’s patients.81 These pharmacies are
known as contract pharmacies.82
Until 2010, only covered entities without an in-house pharmacy were
allowed to contract with a single outside pharmacy to dispense drugs on their
behalf.83 In 2010, HRSA issued guidance allowing all covered entities to contract
with multiple outside pharmacies.84 Covered entities may elect to work with a
contract pharmacy because the entity may not have access to an in-house
pharmacy or the entity may want to supplement its services by using multiple
contract pharmacies to increase patient access to 340B drugs.85
The 340B entity must have a written, signed contract pharmacy agreement
in place with the pharmacy or pharmacies prior to registering the pharmacy or
pharmacies with the 340B Program.86 HRSA notes that the covered entity has,
and continues to bear, full responsibility and accountability for compliance with

79. 340B Drug Pricing Program, FAQs, HEALTH RES. & SERVS. ADMIN.,
https://www.hrsa.gov/opa/faqs/ (last updated Sept. 2018).
80. See Bobby L. Clark et al., The 340B Discount Program: Outpatient Prescription Dispensing
Patterns Through Contract Pharmacies in 2012, 33 HEALTH AFF. 2012, 2013 (2014) (explaining that
covered entities may choose to dispense 340B prescriptions through an in-house pharmacy, single contract
pharmacy, or multiple contract pharmacies).
81. Memorandum from Mary K. Wakefield, Adm’r, Health Res. and Servs. Admin., on Contract
Pharmacy Arrangements in the 340B Program to Stuart Wright, Deputy Inspector General for Evaluation
and Inspections (Feb. 4, 2014) (on file with the Department of Health and Human Services, Office of
Inspector General) [hereinafter Wakefield].
82. Id.
83. See 340B Drug Pricing Program—Contract Pharmacy Services, 75 Fed. Reg. 10,272, 10,273
(Mar. 5, 2010) (permitting covered entities participating in the 340B Drug Pricing Program to use a single
point for pharmacy services, either an in-house pharmacy or individual contract pharmacy).
84. See id. (permitting covered entities to “use multiple pharmacy arrangements as long as they
comply with guidance developed to help ensure against diversion and duplicate discounts . . . .”).
85. See Contract Pharmacy Services, HEALTH RES. & SERVS. ADMIN., https://www.hrsa.gov/
opa/implementation/contract/ (last updated Jan. 2018) (discussing how dispensing 340B drugs to patients
through contract pharmacy services helps facilitate program participation for covered entities without
appropriate “in-house” pharmacy services, and further can serve as supplemental services for covered
entities with access to “in-house” pharmacy services).
86. Notice Regarding 340B Drug Pricing Program—Contract Pharmacy Services, 75 Fed. Reg.
10,272, 10,277–79 (Mar. 5, 2010). Each contract pharmacy is required to register with the OPA to ensure
that drug manufacturers and drug wholesalers are informed of the contract pharmacy agreement. Id. at
10,279. Until the contract pharmacy is approved by the OPA and listed on the 340B database, it is not
eligible to be used by the covered entity. June 2015—Office of Pharmacy Affairs Update, HEALTH RES.
& SERVS. ADMIN., https://www.hrsa.gov/opa/updates/2015/june.html (last updated April 2017).
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all requirements of the 340B Program which includes prevention of the diversion
of covered drugs to individuals other than patients of the covered entity and
duplicate discounts—both statutorily prohibited.87 HRSA states that covered
entities should “engage an independent organization to perform annual audits of
the contract pharmacies and develop comprehensive written contract pharmacy
policies and procedures that include the performance of independent audits of its
contract pharmacies.”88 “In situations where the covered entity is not providing
oversight of its contract pharmacies, HRSA may remove those contract
pharmacies from the 340B Program.”89
Since 2010, there has been a rapid growth in the number of contract
pharmacies which includes retail, specialty, and mail order pharmacies. As of
July 2011, there were more than 7,000 contract pharmacy arrangements in the
340B Program.90 Between 2010 and 2014, the number of pharmacies serving as
contract pharmacies increased by 154 percent.91 According to HRSA, as of
January 2015, the number of contract pharmacy arrangements in the program had
increased to 36,000.92
The increased use of contract pharmacies has contributed immensely to the
growth of the 340B Program. Contract pharmacy arrangements are beneficial to
covered entities for multiple reasons including allowing patients to fill
prescriptions somewhere other than the covered entity and allowing the covered
entity to supplement its services. However, contract pharmacies bring an
increased risk of drug diversion and duplicate discounts due to the complexity of
the arrangements, the expenses of sophisticated inventory tracking systems or
third-party administrators, and the lack of a universal method that can accurately
identify 340B claims.
c. Auditing Covered Entities
All 340B covered entities are required to ensure program integrity and
maintain accurate records documenting compliance with all 340B Program
requirements. Statutorily, HRSA has the authority to audit covered entities to

87. Notice Regarding 340B Drug Pricing Program—Contract Pharmacy Services, 75 Fed. Reg. at
10,278. Drug diversion is when a 340B drug is provided to an individual who is not an eligible patient. A
duplicate discount takes place when a manufacturer is billed for Medicaid rebates on drugs purchased at
a 340B discount. Both are statutorily prohibited and are discussed further in section iv. See discussion
infra Section III.C.iv.
88. August 2016—Contract Pharmacy: Important Tips, HEALTH RES. & SERVS. ADMIN.,
https://www.hrsa.gov/opa/updates/2016/august.html (last updated April 2017).
89. Id.
90. U.S. GOV’T ACCOUNTABILITY OFF., GAO-15-455T, DRUG DISCOUNT PROGRAM: STATUS OF
GAO RECOMMENDATIONS TO IMPROVE 340B DRUG PRICING PROGRAM OVERSIGHT, 9 (2015),
www.gao.gov/assets/670/669188.pdf [hereinafter GAO, DRUG DISCOUNT PROGRAM].
91. MEDPAC, supra note 12, at 9.
92. GAO, DRUG DISCOUNT PROGRAM, supra note 90, at 9 n.21.
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ensure compliance with the 340B Program requirements.93 Covered entities may
be audited by manufacturers as well.94 In addition to audits, 340B entities are
annually required to recertify its eligibility to remain in the program, and its
eligibility to continue purchasing covered outpatient drugs at discounted 340B
prices.95 This is to help ensure compliance with respect to eligibility status, as
well as, compliance with the prohibition against GPOs, duplicate discounts, and
drug diversion. Failure to maintain compliance may result in the covered entity
being liable to manufacturers for refunds of discounts and being removed from
the 340B Program.96
An audit will include, at a minimum: a review of relevant policies and
procedures and how they are operationalized; verification of eligibility, including
GPO and outpatient clinic eligibility; verification of internal controls to prevent
diversion and duplicate discounts, including how the covered entity defines
whether a patient is considered inpatient or outpatient, HRSA Medicaid
Exclusion File designations, and accuracy of covered entity’s 340B database
record; review of 340B Program compliance at covered entity, outpatient or
associated facilities, and contract pharmacies; and testing of 340B drug
transaction records on a sample basis.97
The information collected in the audit must be submitted to HRSA through
the OPA where it is reviewed. After HRSA reviews the audit, it will issue a report
with a request for a corrective action plan (CAP), if necessary. If the covered
entity agrees with the report, then the entity must submit a CAP to HRSA for
approval. If the covered entity disagrees with the report, then the entity must
submit supporting documentation of the entity’s disagreement. OPA will review
the covered entity’s response and, may reissue a report, if necessary. A covered
entity may be removed from the 340B Program if it fails to comply. Once the
findings of the audit and any associated corrective action are finalized, OPA
publishes the report on the OPA website.98 Audit and compliance is a must with
contract pharmacies. The covered entity is required to have fully auditable
records to demonstrate compliance with all 340B Program requirements.99 The
contract pharmacy must provide the covered entity with reports consistent with
customary business practices such as quarterly billing statements, status reports

93. 42 U.S.C. § 256b(a)(5)(C) (2012).
94. Id.
95. Id. § 256b(a)(7)(E).
96. Id. § 256b(a)(5)(D); see also id. § 256b(d)(2)(B)(v)(II) (discussing that where the Secretary
determines there to be a violation, the covered entity will be removed from the drug discount program).
97. Program Integrity, HEALTH RES. & SERVS. ADMIN., https://www.hrsa.gov/opa/programintegrity/index.html (last updated Mar. 2018).
98. Id.
99. Notice Regarding 340B Drug Pricing Program—Contract Pharmacy Services, 75 Fed. Reg.
10,272, 10,273 (Mar. 5, 2010).
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of collections, and receiving and dispensing records.100 “The contract pharmacy,
with the assistance of the covered entity, will establish and maintain a tracking
system suitable to prevent diversion of section 340B drugs to individuals who
are not patients of the covered entity.”101 Customary business records may be
used for this purpose.102 The covered entity must establish a process for periodic
comparison of its prescribing records with the contract pharmacy’s dispensing
records to detect potential irregularities.103 Any 340B Program violations found
during internal or independent audits must be disclosed to HRSA along with the
covered entity’s plan to address the violation.104 A contract pharmacy will be
removed from the 340B Program if the covered entity is not providing oversight
of its contract pharmacy arrangement.105
In a 2011 report, the GAO found that HRSA had not conducted a single
audit in the nearly 20 years of the program’s existence.106 In response, the GAO
recommended HRSA conduct selective audits of 340B covered entities.107 In
2012, HRSA implemented a risk-based and targeted approach to conducting
audits on covered entities. The risk-based audits focused on covered entities
deemed to be at a higher risk of noncompliance “due to the volume of purchases,
increased complexity of the program administration, and use of contract
pharmacies.”108 The targeted audits were triggered by allegations of violations
of 340B requirements, whether through whistleblowers, manufacturers, or selfreported. In 2012, HRSA audited 45 randomly selected covered entities for riskbased audits and six targeted covered entities based on information from
stakeholders.109 The audits encompassed more than 410 outpatient facilities and
860 contract pharmacy locations.110 HRSA has continued to audit covered
entities and posts the results of the audit on its website.111

100. Id. at 10,278.
101. Id.
102. Id.
103. See id. at 10,279 (“Such records can include: Prescription files, velocity report, and records of
ordering and receipt. These records will be maintained for the period of time required by State law and
regulations.”).
104. Id. at 10,274.
105. See id. at 10,278 (stating that a covered entity may be removed from the list of covered entities
and no longer be eligible for 340B pricing because of its participation in drug diversion).
106. See GAO, DRUG PRICING, supra note 9, at 32–33 (explaining that, instead, “the agency largely
relies on participants’ self-policing to ensure compliance with program requirements.”).
107. Id. at 34.
108. U.S. DEPT. OF HEALTH & HUM. SERVS., HEALTH RES. & SERVS. ADMIN., CLARIFICATION OF
HRSA AUDITS OF 340B COVERED ENTITIES (2013), https://www.hrsa.gov/sites/default/files/opa/
programrequirements/policyreleases/auditclarification020813.pdf.
109. GAO, DRUG DISCOUNT PROGRAM, supra note 90, at 10.
110. Id.
111. Contract
Pharmacy
Services,
HEALTH
RES.
&
SERV.’S.
ADMIN.,
https://www.hrsa.gov/opa/implementation/contract/ (last updated Jan. 2018).
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HRSA’s lack of auditing for the first 20 years and the heavy reliance on
self-policing contributed to the failed oversight of HRSA and increased the risk
of noncompliance. The self-policing was problematic because participants in the
340B Program had “little incentive to comply with program requirements,
because few have faced sanctions for noncompliance.”112 Although HRSA has
increased auditing in the last few years, much more is required to ensure program
compliance.
ii. Pharmaceutical Pricing Agreements
To be eligible for the 340B Program, drug manufacturers are required to
enter into a pharmaceutical pricing agreement (PPA) with the Secretary of
HHS.113 PPAs are not transactional, bargained-for contracts.114 Rather, PPAs are
uniform agreements that incorporate statutory obligations and list the
responsibilities of both drug manufacturers and HHS under the 340B Program.115
Participation in the program is conditioned on a manufacturer’s entry into a PPA
for covered drugs purchased by 340B entities.116 The PPAs are similar to the
MDRP agreements whereas they serve as the means by which drug
manufacturers opt into the statutory scheme.117
Once a manufacturer enters into a PPA, that manufacturer is barred from
charging covered entities drug prices exceeding a cap set by HHS.118 This is
known as the ceiling price.119 A manufacturer agrees to charge covered entities
no more than the predetermined price derived from the average and best prices
and rebates calculated under the MDRP.120 If a covered drug is “made available
to any other purchaser at any price,” then manufacturers must offer these drugs
“for purchase at or below the applicable ceiling price” to any covered entity of
the 340B Program.121
a. Ceiling Price
Under the PPA, manufacturers stipulate that they will charge 340B entities
at or below a specified maximum price—the 340B ceiling price. The 340B
ceiling price, based on a statutory cap, represents the maximum price a

112. GAO, DRUG PRICING, supra note 9, at 32–33.
113. 42 U.S.C. § 256b(a) (2012); PhRMA II, 138 F. Supp. 31, 34 (D.D.C. 2015).
114. Astra USA, Inc. v. Santa Clara Cty., Cal., 563 U.S. 110, 113 (2011).
115. Id.
116. Id.
117. Astra, 536 U.S. at 113.
118. 42 U.S.C. § 256b(a)(1).
119. See 42 U.S.C. § 1396r-8(c) (stating how to calculate the ceiling price); id. § 1396r-8(c)(2)(D)
(capping the total possible rebate percentage at 100 percent of the price of the drug).
120. Astra, 563 U.S. at 115; 42 U.S.C § 256(a)(1).
121. 42 U.S.C. § 256b(a)(1).
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manufacturer can charge for a 340B drug.122 Ceiling prices are guaranteed
whether the 340B entity purchases drugs directly from manufacturers or through
a wholesaler. The ceiling prices and key data used to calculate them are
proprietary and are not shared with the general public. The MDRP’s statute
prohibits “HHS from disclosing pricing information in a form that could reveal
the prices a manufacturer charges for drugs it produces.”123 However, the ACA
requires HHS to give covered entities access to some of the information
submitted by manufacturers.124
The 340B ceiling price is statutorily defined as the Average Manufacturer
Price (AMP) reduced by the rebate percentage—commonly referred to as the
Unit Rebate Amount (URA).125 HRSA obtains the AMP and URA data from
CMS as part of quarterly reporting for the MDRP.126 Both HRSA and drug
manufacturers separately calculate 340B ceiling prices each quarter by using the
same statutorily-defined formula and the drug pricing data that manufacturers
report to the CMS. The 340B ceiling price is specific to each 11-digit National
Drug Code (NDC).
Defined under the MDRP, the AMP means the average price paid to the
manufacturer for the drug by (i) wholesalers for drugs distributed to retail
community pharmacies; and (ii) retail community pharmacies that purchase
drugs directly from the manufacturer.127 The AMP is calculated from the
preceding calendar quarter for the smallest unit of measure.128 Manufacturers
report these prices as proprietary information to CMS and may be subject to audit
by HHS.
The URA is the amount of Medicaid rebate due for each unit of a drug.129
HRSA calculates URAs using a statutory formula that is based on the formula
used to calculate Medicaid drug rebates.130 The statutory formula for the URA
122. 42 U.S.C. § 256b(a)(1). Manufacturers may sell a drug at a price that is lower than the ceiling
price. Id. Additionally, covered entities may negotiate with manufacturers in order to pay prices below the
ceiling price.
Overview of the 340B Drug Pricing Program, 340B Health,
https://www.340bhealth.org/members/340b-program/overview/ (last visited Oct. 28, 2018).
123. Astra, 563 U.S. at 121; 42 U.S.C. § 1396r-8(b)(3)(D).
124. Patient Protection and Affordable Care Act Pub. L. No. 111-148, § 7102, 124 Stat. 119, 824
(2010) (codified as amended at 42 U.S.C. 256b(d)); 42 U.S.C. § 256b(d)(1)(B)(i)(I); Astra, 563 U.S. at
121 n.8.
125. 340B
Ceiling
Price
Calculation,
HEALTH
RES.
&
SERVS.
ADMIN.,
https://www.hrsa.gov/opa/updates/2015/may.html (last updated Apr. 2017); 42 U.S.C. § 256b(a)(1).
126. 42 U.S.C. § 1396r-8(a)(1). Manufacturers are required to submit their average manufacturer price
(AMP) and their best price for each respective dosage form and strength of all prescription drugs to CMS
as part of quarterly reporting for the MDRP. Id.
127. Id. § 1396r-8(k)(1)(A).
128. Id. § 256b(a)(1).
129. See Unit Rebate Amount Calculation, MEDICAID, https://www.medicaid.gov/medicaid/
prescription-drugs/medicaid-drug-rebate-program/unit-rebate-calculation/index.html (last visited Oct. 26,
2018).
130. Id. § 1396r-8.
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varies based on whether the drug is categorized as a single-source, innovator
multiple-source drug, a non-innovator multiple-source drug, a clotting factor, or
exclusively pediatric drug.131 For single-source and multiple-source innovator
drugs, the URA is the greater of (i) 23.1 percent of the AMP per unit or (ii) the
difference between the AMP and the best price per unit; adjusted by the
Consumer Price Index-Urban (CPI-U) based on launch date and current quarter
AMP.132 For multiple-source non-innovator drugs, the URA equals 13 percent of
the AMP per unit.133 For clotting factors or exclusively pediatric drugs, the URA
is the greater of (i) 17.1 percent of the AMP per unit or (ii) the difference between
the AMP and the best price per unit; adjusted by the CPI-U based on launch date
and current quarter AMP.134
This figure is then multiplied by the package size and case package size to
produce a price for the drugs.135
340B Ceiling Price = [(AMP) – (URA)] x Drug Package Size
The ceiling price is calculated at the smallest unit of measure, to six decimal
places.136 HRSA is required to publish all 340B ceiling prices, rounded to two
decimal places.137 The URA can equal but not exceed 100 percent of the AMP
for a period.138 If the formula yields a price of zero or a negative number for a
340B drug, then HRSA has instructed manufacturers to set the price for that drug
at a penny for the smallest unit of measure for that quarter—this has become
known as HRSA’s “Penny Pricing Policy.”139 In 2017, HRSA published

131. Id. CMS’ Medicaid Drug Rebate (MDR) system performs the URA calculation using the drug
manufacturer’s pricing. The specific methodology used is determined by law and depends upon whether
a drug is classified as single source, i.e., drugs for which there are no generic alternatives available on the
market, innovator multiple-source, i.e., drugs that have FDA New Drug Application approval and for
which there exists generic alternatives on the market, non-innovator multiple source, i.e., drugs that do
not have FDA New Drug Application approval and are, in effect, generic drugs, a clotting factor drug, or
an exclusively pediatric drug. Medicaid Drug Rebate Program, MEDICAID.GOV,
https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html (last
updated Sept. 11, 2018).
132. 42 U.S.C. § 1396r-8(c)(1) (2012). The URA for single-source and innovator multiple-source
drugs is the greater of (AMP x 23.1%) or (AMP – the best price). Id.
133. 42 C.F.R. § 447.509(a)(6)(ii) (2016).
134. Id. §1396r-8(c)(1)(B)(iii).
135. Id. For example, the AMP minus the URA indicates the cost of one pill. HRSA calculates the
price of the total number of pills in the bottle (package size), and then the price of the multiple packages
(case package size), which results in the 340B ceiling price and the corresponding quantity at which
covered entities actually purchase the covered outpatient drug. Id.
136. 42 C.F.R. § 10.10 (2017).
137. 340B Drug Pricing Program Ceiling Price and Civil Monetary Penalties Regulation, 82 Fed. Reg.
45,511 (Jan. 5, 2017) (codified at 42 C.F.R. pt. 10).
138. Id.
139. See id. (When the URA equals the AMP, the price for 1 unit of the drug would be $.01).
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regulations specifying how the 340B ceiling price is calculated for a drug—
including commentary on HRSA’s Penny Pricing Policy—and creating
standards for imposing civil monetary penalties (CMPs) on manufacturers that
knowingly and intentionally overcharge covered entities.140
b. Prime Vendor Programs (PVP)
The 340B Program requires HRSA to establish a Prime Vendor Program
(PVP).141 “The purpose of the PVP is to develop, maintain, and coordinate a
program capable of distribution, facilitation, and other activities in support of the
340B Program.”142 The PVP assists HRSA with the administration of the 340B
Program and is managed by contractors. HRSA currently contracts with a
company called Apexus to manage the PVP.143
The PVP establishes a distribution network for pharmaceuticals to covered
entities and negotiates prices for a portfolio of drugs below the 340B price.144
Apexus can negotiate sub-ceiling prices on 340B drugs with manufacturers by
pooling the purchasing power of covered entities. “The PVP is a voluntary
program for 340B covered entities and serves its participants in three primary
roles: (1) negotiating sub-340B pricing on pharmaceuticals; (2) establishing
distribution solutions and networks that improve access to affordable
medications; and (3) providing other value-added products and service.”145 “As
of April 2014, about 82 percent of covered entities participated in the PVP and
accounted for $5 billion in 340B drug purchases.”146
iii. Patients of the Entity
Under the 340B Program, covered entities may only provide 340B drugs to
individuals who are eligible patients of the entity.147 However, the statute does
not define the term “patient.” Due to the large number of covered entities and the
wide diversity of eligible groups, the definition of a “patient” required flexibility

140. See generally 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary
Penalties Regulation, 82 Fed. Reg. 1210 (Jan. 5, 2017) (codified at 42 C.F.R. pt. 10).
141. 42 U.S.C. §256b(a)(8) (2012).
142. 340B Drug Pricing Program, FAQs, HEALTH RES. & SERVS. ADMIN., https://www.hrsa.gov/
opa/faqs/ (last updated Sept. 2018).
143. About the PVP, APEXUS, https://www.340bpvp.com/about/ (last visited Oct. 28, 2018).
144. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties
Regulation, 82 Fed. Reg. at 1229–30.
145. 340B Drug Pricing Program, FAQs, HEALTH RES. & SERVS. ADMIN.,
https://www.hrsa.gov/opa/faqs/ (last updated Sept. 2018).
146. MEDPAC, supra note 12, at 7.
147. See 42 U.S.C. § 256b(a)(5)(B) (“[A] covered entity shall not resell or otherwise transfer the drug
to a person who is not a patient of the entity.”).

44

JOURNAL OF HEALTH CARE LAW & POLICY

[VOL. 22:25

to ensure it covered each covered entity’s patients.148 In 1996, HRSA issued
guidance on the 340B Program definition of patient.149 In summary, an
individual is a “patient” of a covered entity—with the exception of state-operated
or funded AIDS drug purchasing assistance programs—only if: (1) the covered
entity has established a relationship with the individual, such that the covered
entity maintains records of the individual’s health care; and (2) the individual
receives health care services from a health care professional who is either
employed by the covered entity or provides health care under contractual or other
arrangements—e.g. referral for consultation—such that responsibility for the
care provided remains with the covered entity; and (3) the individual receives a
health care service or range of services from the covered entity which is
consistent with the service or range of services for which grant funding or
Federally-qualified health center look-alike status has been provided to the
entity—DHSs are exempt from this requirement.150 Under this definition,
covered entities are subject to all three requirements; hospitals are only subject
to the first two.
An individual will not be considered a patient of the entity for purposes of
340B if the only health care service received by the individual from the covered
entity is the dispensing of a drug or drugs for subsequent self-administration or
administration in the home setting.151 In cases where an individual has received
health care services from a non-covered entity resulting in a prescription, the
administrative act of recording such information, incorporating it into the health
record, and filling the prescription does not constitute health care services for the
patient’s health care for purposes of the 340B Program. If the outpatient is
referred to a specialist, the patient is covered under 340B as long as the covered
entity has responsibility for the patient.
In 2007, HSRA determined that “some 340B covered entities may have
interpreted the definition too broadly, resulting in the potential for diversion of
medications purchased under the 340B Program.”152 HRSA published proposed
guidance intended to clarify the definition of a patient and update the 1996
guidance.153 HRSA determined the clarification was necessary to “protect the

148. Notice Regarding Section 602 of the Veterans Healthcare Act of 1992 Patient and Entity
Eligibility, 61 Fed. Reg. 55,156, 55,157–58 (Oct. 24, 1996).
149. Id.
150. Id.
151. See id. at 55,158 (stating that, “[a]n individual registered in a State operated or funded AIDS drug
purchasing assistance program receiving financial assistance under Title XXVI of the PHS Act will be
considered a ‘patient’ of the covered entity for purposes of this definition if so registered as eligible by
the state program.”).
152. See Section 602 of the Veterans Health Care Act of 1992 Definition of “Patient,” 72 Fed. Reg.
1543, 1544 (Jan. 12, 2007) (stating that under 340B it is illegal for covered entities to sell medications
purchased under the program to persons who are not considered “patients” of the covered entity).
153. Id.
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integrity of the 340B Program and to assist covered entities and other participants
in their compliance efforts.”154 However, HRSA withdrew this proposal
following a May 2014 federal district court ruling.155 Again in 2015, HRSA
attempted to update the definition, but ultimately withdrew the proposal in
January 2017.
The definition of patient is one of the key issues with the 340B Program.
The current definition is outdated and problematic due to ambiguity. Moreover,
the current definition allows anyone, regardless of wealth or insurance, to qualify
for 340B discounted drugs. An updated definition is necessary in order to ensure
covered entities remain in compliance and cut down on drug diversion.
iv. Covered Drugs
The 340B Program limits the price that manufacturers may charge certain
covered entities for covered outpatient drugs; inpatient services are not
covered.156 A covered outpatient drug, defined in § 1927(k) of the Social Security
Act, is summarized as FDA-approved prescription drug; over-the-counter (OTC)
drugs written on a prescription; biological products that can be dispensed only
by a prescription other than a vaccine; or FDA-approved insulin.157 The term
excludes inpatient drugs and drugs that are bundled with other services for
payment purposes.
Covered entities have the responsibility to ensure that drugs purchased
under the 340B Program are limited to outpatient use. Whether a drug qualifies
as outpatient depends upon the factual circumstances surrounding the care of that
particular individual. A hospital is required to develop appropriate tracking
systems to ensure that covered outpatient drugs purchased through the 340B
Program are not used for hospital inpatients. Proper tracking is critical in “mixeduse” settings, such as surgery departments, cardiac catheter labs, infusion
centers, and emergency departments, where both inpatients and outpatients are
treated. The entity is responsible for the use of the drugs and auditable records
that demonstrate compliance with 340B Program requirements.158
a. Drug Diversion and Duplicate Discount
The 340B Program forbids covered entities from reselling or otherwise
transferring 340B discounted drugs to an individual who is not a patient of the

154. Id. at 1543.
155. See PhRMA I, 43 F. Supp. 3d 28, 31 (D.D.C. 2014) (holding that the Secretary of Health and
Human Services lack the statutory authority to implement the orphan drug rule at issue in this case).
156. 42 U.S.C. § 256b(b)(2) (2012).
157. 42 U.S.C. § 1396r-8(k)(2); 42 U.S.C. § 256b(b)(2)(A).
158. 340B Drug Pricing Program, FAQs, HEALTH RES. & SERVS. ADMIN.,
https://www.hrsa.gov/opa/faqs/ (last updated Sept. 2018).
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entity.159 Drug diversion occurs when a 340B drug is provided to an individual
who is not an eligible patient. Thus, if a covered entity receives a 340B discount
on a drug, then the entity may not “resell or otherwise transfer” the drug to
anyone who is not a patient of the entity.160 Covered entities are subject to audits
and sanctions for violations of the diversion prohibition.161
Known as duplicate discounts, manufacturers may not provide a discounted
340B price and a Medicaid drug rebate for the same drug.162 In other words,
manufacturers may not be billed for Medicaid rebates on drugs purchased at a
340B discount. Covered entities are required to have a mechanism in place to
prevent duplicate discounts.163
To help ensure that covered entities avoid duplicate discounts, when an
entity is enrolled in the 340B Program, the entity must choose to “carve-in” or
“carve-out” Medicaid patients. An entity that carves in their Medicaid patients
should provide 340B drugs for their Medicaid patients and the state Medicaid
program is not allowed to claim the rebates.164 An entity that carves out their
Medicaid patients will purchase drugs for their Medicaid patients through other
means and the state Medicaid program is permitted to claim rebates on the
drugs.165
“HRSA maintains a file of covered entities that carve in Medicaid patients
to help state Medicaid agencies identify claims for 340B drugs and prevent
duplicate discounts.”166 If a covered entity decides to bill Medicaid for drugs
purchased under 340B, then all drugs billed under their Medicaid provider
number or National Provider Identifier (NPI), must be listed in the HRSA
Medicaid Exclusion File (MEF).167 Covered entities that choose to carve-out—
i.e. opt to purchase Medicaid drugs outside of the 340B Program—must ensure
that all drugs billed under their Medicaid provider number or NPI are not listed
in the MEF.
The MEF allows for states and manufacturers to see which drugs are not
subject to Medicaid rebates and helps prevent duplicate discounts. Covered

159. 42 U.S.C. § 256b(a)(5)(B).
160. Id.
161. Id. § 256b(a)(5)(C)–(D).
162. Id. § 256b(a)(5)(A)(i).
163. Id. § 256b(a)(5)(A)(ii).
164. See MEDPAC, supra note 12, at 7 (“In 2013, 65 percent of hospital sites and 37 percent of
nonhospital sites provided 340B drugs to Medicaid patients, i.e. carved in Medicaid patients.”).
165. Duplicate Discount Prohibition, HEALTH RES. & SERVS. ADMIN., https://www.hrsa.gov/opa/
programrequirements/medicaidexclusion/index.html (last updated Sept. 2017).
166. MEDPAC, supra note 12, at 9.
167. Duplicate
Discount
Prohibition,
HEALTH
RES.
&
SERVS.
ADMIN.
https://www.hrsa.gov/opa/programrequirements/medicaidexclusion/index.html (last updated Sept. 2017).
Adopted under HIPAA, the NPI is a unique identification number for covered health care providers issued
by the Centers for Medicare and Medicaid Services. 45 C.F.R. § 162.406 (2005).
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entities may request to change either their carve-in decision or the specific
identifiers listed in the MEF at any time.168 These requests take effect the
following quarter pending the approval by OPA.169 The covered entities are
responsible for ensuring the information in the MEF is accurate each quarter and
at the time of annual recertification.170
Covered entities are required to permit HRSA and manufacturers to audit
records that directly pertain to compliance with the prohibition of resale/transfer
or double discounts.171 HRSA may terminate the manufacturer’s PPA if found to
be overcharging a covered entity, which would also terminate the manufacturer’s
eligibility for Medicaid coverage.172
v. No Restriction on Revenue
The 340B statute does not restrict how covered entities may use revenue.
The 340B Program does not prohibit covered entities from providing 340B drugs
to individuals with Medicare or private insurance so long as the individual is a
qualifying patient of the covered entity and the drug is not subject to a duplicate
discount under Medicaid. Furthermore, a patient’s income does not affect
whether the patient is covered by the 340B Program.
Under the 340B Program, a covered entity may generate revenue when
reimbursement for the covered outpatient drugs exceeds the discounted prices
the entity paid for the drugs.173 Covered entities may use these funds to expand
the number of patients served, increase the scope of services offered to lowincome and other patients, invest in capital, cover administrative costs, or for any
other purpose.174 Moreover, HRSA does not have the statutory authority to track
how entities use this revenue.175
Financial incentives drive both drug manufacturers and covered entities.
The original intent of the 340B Program is to help uninsured, indigent patients
by giving qualifying health care facilities access to discounts for outpatient
drugs.176 However, as the program grows, there are incredible financial
incentives for both sides.

168. Duplicate
Discount
Prohibition,
HEALTH
RES.
&
SERVS.
ADMIN.,
https://www.hrsa.gov/opa/programrequirements/medicaidexclusion/index.html (last updated Sept. 2017).
169. Id.
170. Id.
171. 42 U.S.C. § 256b(a)(5)(C) (2012).
172. 42 U.S.C. § 1396r-8(b)(4)(B).
173. MEDPAC, supra note 12, at 8.
174. Id.
175. Id.
176. Our View: 340B Benefits Vulnerable Patients, Essential Hospitals, Taxpayers, AMERICA’S
ESSENTIAL HOSPITALS (March 2016), http://essentialhospitals.org/wp-content/uploads/2016/03/OurView-340B-March-2016.pdf.
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III. CURRENT STATE OF AFFAIRS OF THE 340B DRUG PRICING
PROGRAM
A. Recent Growth
Since the 340B Program was established in 1992, it has grown rapidly
through both Congressional action and administrative action.177 Most recently,
the 340B Program expanded in 2010 under the ACA.178 This expansion included
expanding the eligibility of Medicaid, the beginning of multiple contract
pharmacies, and broadening the eligibility of covered entities.179 “According to
HRSA officials, as of 2015 more than 11,000 covered entities were participating
in the 340B Program—an increase of approximately 30 percent since 2008.”180
Every state and the District of Columbia has 340B hospitals.181 Furthermore, in
a November 2014 white paper analyzing the growth of the 340B Program, the
Berkeley Research Group (BRG) predicted growth to be greater than $11 billion
by 2019.182 Yet, in 2015, discounted purchases made under 340B hit $12
billion.183
B. The Patient Protection and Affordable Care Act
In 2010, the 111th United States Congress enacted the Patient Protection
and Affordable Care Act (ACA).184 The ACA—as amended by section 2302 of
the Health Care and Education Reconciliation Act (HCERA)—made several
notable changes to the 340B Program including expanded participation in the
program and expanded regulations in order to ensure 340B integrity.185 The ACA
not only expands Medicaid, but also state-level expansions in state-level
Medicaid.186 As a result, the ACA expands the scope of the Medicaid program

177. ANDREW W. MULCAHY ET AL., THE 340B PRESCRIPTION DRUG DISCOUNT PROGRAM: ORIGINS,
IMPLEMENTATION, AND POST-REFORM FUTURE, 5 fig.3, 6 (2014).
178. Id. at 6.
179. Id. at 5–6 (discussing the extension of eligibility to critical access hospitals, sole community
hospitals, rural referral centers, and cancer centers).
180. GAO, DRUG DISCOUNT PROGRAM, supra note 90, at 1.
181. List of 340B Hospitals by State, 340B HEALTH, http://advocacy.340bhealth.org/340Bhospitallists
(last updated Apr. 2018).
182. AARON VANDERVELDE, GROWTH OF THE 340B PROGRAM: PAST TRENDS, FUTURE
PROJECTIONS 2 (2014).
183. Adam J. Fein, 340B Purchases Hit $12 Billion in 2015—and Almost Half of the Hospital Market,
DRUG CHANNELS (Feb. 23, 2016), https://www.drugchannels.net/2016/02/340b-purchases-hit-12billion-in.html.
184. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010).
185. §§ 7101(a), 7102(a), 124 Stat. at 821–25.
186. A 50-State Look at Medicaid Expansion, FAMILIES USA (May 2018),
https://familiesusa.org/product/50-state-look-medicaid-expansion.
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and increases the number of individuals states must cover.187 The number of
Medicaid patients served by a hospital affects its DSH adjustment percentage,
which helps determine hospital eligibility for the 340B program.188
i. Expanded Entities
The ACA expanded the 340B Program by expanding entity eligibility for
the program to include additional types of hospitals such as certain children’s
hospitals and free-standing cancer hospitals, critical access hospitals (CAHs),
rural referral centers (RRCs), and sole community hospitals (SCHs).189
In 2010, HCERA190 excluded orphan drugs from 340B pricing applicable
to the newly added hospitals.191 Due to an ambiguity, covered entities contended
orphan-designated drugs should be included in the 340B Program for the newly
added covered entities, while drug manufacturers contended that all orphandesignated drugs should be excluded from the 340B Program for the newly added
covered entities.192 This disagreement was the catalyst of two court battles.193
ii. Expanded Regulations—Improvements to 340B Program Integrity
a. Overview
In addition to expanding eligibility for covered entities, the ACA contained
provisions to improve 340B Program integrity.194 The ACA explicitly authorized
HRSA to issue regulations and provided for more rigorous enforcement.195 Prior
to the ACA, 340B did not explicitly provide authority for HRSA to issue
regulations. HRSA simply “used interpretive guidance and statements of policy
to provide guidance since the inception of the program and to create a working
framework for its administration.”196 Under the ACA, Congress “chose to
strengthen and formalize HRSA’s enforcement authority.”197

187. Medicaid Enrollment Changes Following the ACA, MEDICAID & CHIP PAYMENT & ACCESS
COMM., https://www.macpac.gov/subtopic/medicaid-enrollment-changes-following-the-aca/.
188. GAO, DRUG PRICING, supra note 9, at 27 n.62.
189. § 7101(a), 124 Stat. at 821–22; 42 U.S.C. § 256b(a)(4)(M)–(O) (2012).
190. Health Care and Education Reconciliation Act of 2010, Pub. L. No. 111-152, 124 Stat. 1029
(2010). The Act was signed into law by President Barack Obama on March 30, 2010.
191. § 2302, 124 Stat. at 1083.
192. PhRMA I, 43 F. Supp. 3d 28, 33–34 (D.D.C. 2014).
193. PhRMA I, 43 F. Supp. 3d at 39; PhRMA II, 138 F. Supp. 3d 31, 48–49 (D.D.C. 2015).
194. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7102, 124 Stat. 119 823–26
(2010) (codified as amended 42 U.S.C. § 256b (2012)).
195. Id.
196. Notice Regarding 340B Drug Pricing Program—Contract Pharmacy Services, 75 Fed. Reg.
10,272, 10,273 (Mar. 5, 2010).
197. Astra USA, Inc. v. Santa Clara Cty., Cal., 563 U.S. 110, 121–22 (2011).
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b. Ceiling Price Calculation
Section 7102 of the ACA required HHS to develop a system to enable HHS
to verify the accuracy of ceiling prices charged to covered entities which are
calculated and reported by manufacturers.198 HHS was required to develop and
publish “precisely defined standards and methodology for the calculation of
ceiling prices.”199 This rule favored covered entities by assisting in obtaining
refunds when overcharged by drug manufacturers.200 HRSA published a notice
of proposed rulemaking in June 2015.201 After closing the public comment period
in August 2015, HRSA reopened the comment period for additional comments
in April 2016.202 In January 2017, HRSA published the final rule addressing the
ceiling price calculations.203
First, the guidance adopts the statutory formula for calculating the 340B
ceiling price—AMP for the smallest unit of measure minus URA.204 The final
rule also indicates that the terms “package size” and “case package size” were
removed.205 HHS plans to address these operational elements concerning the
340B ceiling price calculation in a future guidance associated with the 340B
Program ceiling price reporting system.206
Next, the guidance finalized HRSA’s Penny Pricing policy.207 When ceiling
price calculations result in a ceiling price that equals zero, the 340B ceiling price
will be set at $0.01—one penny.208 HRSA indicated that the “long-standing
policy reflects a balance between the equities of different stakeholders and
establishes a standard pricing method in the market.”209 HRSA indicated “any
alternatives to penny pricing would violate the 340B ceiling price formula and
would reward manufacturers for raising prices faster than inflation.”210

198. § 7102, 124 Stat. at 826.
199. 42 U.S.C § 256b(d)(1)(B)(i)(I) (2012).
200. Id. § 256b(d)(1)(B)(ii).
201. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties
Regulation, 80 Fed. Reg. 34,583, 34,583 (proposed June 17, 2015) (to be codified 42 C.F.R. pt. 10).
202. See 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties
Regulation; Reopening of Comment Period, 81 Fed. Reg. 22,960, 22,960 (Apr. 19, 2016) (to be codified
at 42 C.F.R. pt. 10).
203. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties
Regulation, 82 Fed. Reg. 1210 (Jan. 5, 2017) (to be codified as 42 C.F.R. pt. 10).
204. Id. at 1213.
205. Id. at 1214.
206. Id.
207. See id. at 1215–17 (noting commenters’ opposition to penny pricing, but finding that it best
effectuates the statutory scheme); Press Release, Dept. of Health & Human Res., Clarification of Penny
Pricing Policy (Nov. 21, 2011) (on file with Department of Health & Human Resources).
208. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties
Regulation, 82 Fed. Reg. at 1215.
209. Id.
210. Id.

2019]

TWO-AND-A-HALF DECADES OF UNCERTAINTY

51

Finally, the guidance addressed pricing when a new drug is introduced.211
In general, the calculation of the ceiling price is based on the pricing data from
the immediately preceding calendar quarter; however, for new drugs that data is
not available. Thus, HRSA determined a new drug’s AMP will be calculated
within 30 days into the second quarter following its release.212 Once the AMP is
calculated, drug manufacturers must contact the covered entities that overpaid
for a drug and offer repayment for the difference within 120 days.213 If a
manufacturer fails to refund a covered entity within 120 day, then the
manufacturer may be deemed to have knowingly and intentionally overcharged
the covered entity resulting in civil monetary penalties.214
HRSA published the final rule in January 2017, however, because 340B
ceiling prices are calculated on a quarterly basis, HRSA intended to begin
enforcing the rule beginning with prices offered April 1, 2017. On January 20,
2017, the Trump administration issued a Memorandum—entitled “Regulatory
Freeze Pending Review”—directing agencies to temporarily postpone the
effective date of regulations that had been published in the Federal Register but
had not yet taken effect.215 HHS initially delayed the effective date of the final
rule to May 22, 2017, but subsequently changed the effective date of the final
rule to July 1, 2018.216
c. Civil Monetary Penalties—CMPs
The ACA also required HHS to develop and issue regulations for the 340B
Program that established standards for the imposition of sanctions in the form of
civil monetary penalties (CMPs) for manufacturers that knowingly and
intentionally overcharge a covered entity for a 340B drug.217 The CMPs shall not
exceed $5,000 for each instance of overcharge to a covered entity.218 In
September 2010, HRSA issued an advanced notice of proposed rulemaking on

211. Id. at 1217.
212. Id. at 1213. Prior to this guidance, drug manufacturers would estimate the ceiling price on a new
drug. If the estimated price was higher than the eventually calculated AMP, then covered entities would
have to pursue refunds. 340B Drug Pricing Program Ceiling price and Manufacturer Civil Monetary
Penalties Regulation, 80 Fed. Reg. 34,583, 34,585 (proposed June 17, 2015) (to be codified at 40 C.F.R.
pt. 10).
213. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties
Regulation, 82 Fed. Reg. at 1218.
214. Id. at 1224.
215. Memorandum for the Heads of Executive Departments and Agencies; Regulatory Freeze Pending
Review, 82 Fed. Reg. 8346, 8346 (Jan. 24, 2017).
216. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties
Regulation, 82 Fed. Reg. 14,332, 14,333 (Mar. 20, 2017) (to be codified at 42 C.F.R. pt. 10); 340B Drug
Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation, 82 Fed. Reg.
45,511, 45,512 (Sept. 29, 2017) (to be codified at 42 C.F.R. pt. 10).
217. 42 U.S.C. § 256b(d)(1)(B)(vi)(III) (2012).
218. 42 U.S.C. § 256b(d)(1)(B)(vi)(II).
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establishing the standards.219 HRSA acknowledged that the regulations presented
“a number of issues” since HRSA never had civil monetary penalty authority that
addressed manufacturing overcharging of the 340B Program.220 Prior to the
ACA, HRSA handled overcharge complaints through informal procedures.221
However, the ACA directed HHS to develop formal procedures for resolving
overcharge claims.222 In June 2015, HHS issued notice of proposed rule set for
the application of civil monetary penalties.223 In January 2017, HRSA issued a
final rule on the 340B Manufacturer Civil Monetary Penalties Regulation.224
HRSA did not define the terms “knowingly” or “intentionally” in order to
allow the Office of the Inspector General (OIG) the “necessary flexibility to
evaluate each instance of overcharge on a case-by-case basis.”225 HRSA listed
several examples where it would not assume a manufacturer “knowingly and
intentionally” overcharged a covered entity including: an isolated inadvertent,
unintentional, or unrecognized error in calculating the 340B ceiling price; drug
sales of a new drug during the estimation period that are higher than the later
calculated price, so long as manufacturers issued a refund; sales made to a
covered entity that did not identify as 340B-eligible at the time of purchase; and
sales when a covered entity chooses to order non-340B priced drugs and the order
is not due to a manufacturer’s refusal to sell or make drugs available at the 340B
price.226 HRSA stated that specific intent to violate the 340B statute was not
necessarily required to warrant the CMP.227 Manufacturers are responsible for
340B overcharges even if drugs are sold through a third party such as a
wholesaler.228
The guidance was released on January 5, 2017 and enforcement of the rule
was to begin on April 1, 2017. However, on January 20, 2017, the Trump
administration issued a Memorandum—entitled “Regulatory Freeze Pending
Review”—directing agencies to temporarily postpone the effective date of

219. 340B Drug Pricing Program Manufacturer Civil Monetary Penalties, 75 Fed. Reg. 57,230,
57,230–31 (Sept. 20, 2010) (to be codified at 42 C.F.R. ch. 1).
220. Id. at 57,231.
221. Manufacturer Audit Guidelines and Dispute Resolution Process 0905–ZA–19, 61 Fed. Reg.
65,406, 65,412 (Dec. 12, 1996); Astra USA, Inc. v. Santa Clara Cty., Cal., 563 U.S. 110, 115–16 (2011).
222. See 42 U.S.C. § 256b(d)(3)(A) (“Not later than 180 days after March 23, 2010, the Secretary shall
promulgate regulations to establish and implement an administrative process for the resolution of claims
by covered entities that they have been overcharged for drugs purchased . . . and claims by manufacturers,
after the conduct of audits[.]”).
223. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties
Regulation, 80 Fed. Reg. 34,583 (June 17, 2015) (to be codified at 42 C.F.R. pt. 10).
224. 340B Drug Pricing Program Ceiling Price and Civil Monetary Penalties Regulation, 82 Fed. Reg.
1210 (Jan. 5, 2017) (to be codified at 42 C.F.R. pt. 10).
225. Id. at 1222.
226. Id. at 1221.
227. Id. at 1222.
228. Id. at 1224.

2019]

TWO-AND-A-HALF DECADES OF UNCERTAINTY

53

regulations that had been published in the Federal Register but had not yet taken
effect.229 HHS initially delayed the effective date of the final rule to May 22,
2017, but subsequently changed the effective date of the final rule to July 1,
2018.230
d. Administrative Dispute Resolution—ADR
Under the ACA, Congress directed HHS to create an administrative dispute
resolution process for the 340B Program.231 Prior to the ACA, the program
followed an informal dispute resolution process from 1996.232 HHS was tasked
with establishing a binding administrative dispute resolution process to resolve
claims raised by covered entities and drug manufacturers.233 HHS was directed
to “promulgate regulations to establish and implement an administrative process
for the resolution of claims by covered entities that they have been overcharged
for drug” and “claims by manufacturers” following an audit.234 The process was
to include “appropriate procedures for the provision of remedies and
enforcement of determinations made pursuant to such process through
mechanisms and sanctions.”235These sanctions included civil monetary penalties
of up to “$5,000 for each instance of overcharging a covered entity that may have
occurred.”236
HHS was tasked to promulgate the regulations within 180 days of the
ACA—March 23, 2010.237 On September 20, 2010, HRSA issued a notice of
proposed rulemaking to establish the process.238 In 2015, HRSA stated that
“[f]uture rulemaking will address the administrative dispute resolution
process.”239 In August 2016, HRSA released a notice of a proposed rule to
formally regulate the ADR process for reviewing claims and resolving disputes

229. Memorandum for the Heads of Executive Departments and Agencies; Regulatory Freeze Pending
Review, 82 Fed. Reg. 8346, 8346 (Jan. 24, 2017).
230. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties
Regulation, 82 Fed. Reg. 14,332, 14,332–33 (Mar. 20, 2017) (to be codified at 42 C.F.R. pt. 10); 340B
Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation, 82 Fed. Reg.
45,511, 45,511–13 (Sept. 29, 2017) (to be codified at 42 C.F.R. pt. 10).
231. 42 U.S.C. § 256b(d)(3) (2012).
232. See Manufacturer Audit Guidelines and Dispute Resolution Process, 61 Fed. Reg. 65,406, 65,406
(Dec. 12, 1996) (informing interested parties about the final guidelines regarding the informal dispute
resolution process).
233. 42 U.S.C. § 256b(d)(3).
234. Id.
235. Id.
236. 42 U.S.C. § 256b(d)(1)(B)(vi)(II)).
237. 42 U.S.C. § 256b(d)(3)(A).
238. 340B Drug Pricing Program Administrative Dispute Resolution Process, 75 Fed. Reg. 57,233
(Sept. 20, 2010) (to be codified at 42 C.F.R. ch. 1).
239. 340B Drug Pricing Omnibus Guidance, 80 Fed. Reg. 52,300, 52,301 (Aug. 28, 2015).
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under the 340B Program.240 The proposed rule addressed the establishment and
implementation of a binding ADR process for certain disputes arising under the
340B Program.241
“The purpose of the ADR process is to resolve (1) claims by covered
entities that they have been overcharged for covered outpatient drugs by
manufacturers; and (2) claims by manufacturers, after a manufacturer has
conducted an audit, that a covered entity has violated the prohibition on drug
diversion patients or duplicate discounts.”242 The proposed rule also established
an Administrative Dispute Resolution Panel or 340B ADR Panel.243
The proposed rule was intended to replace the informal dispute resolution
from 1996—over 20 years ago. Comments were invited until October 2016.
However, no final notice has been issued.
e. Astra
The importance of having a formalized ADR is illustrated by Astra USA,
Inc. v. Santa Clara Cnty., Cal.244 Under Astra, 340B entities may not bring
lawsuits against drug manufacturers alleging they have been overcharged for the
drugs purchased from the manufacturers pursuant to the PPA. The Supreme
Court found no private right of action under the 340B Program. Astra made clear
that covered entities were required to rely on the informal dispute resolution
process prior to the guidance which left covered entities with few options when
manufacturers overcharge them.
In 2006, Santa Clara County, California filed suit against Astra USA, Inc.
and eight other pharmaceutical companies in Cty. of Santa Clara v. Astra USA,
Inc.245 County and county operated medical facilities brought action against
pharmaceutical manufacturers alleging that they had been overcharged for
certain covered drugs in violation of the PPAs between the federal government
and manufacturers. The United States District Court for the Northern District of
California dismissed the complaint.246 On appeal, the United States Court of
240. 340B Drug Pricing Program; Administrative Dispute Resolution, 81 Fed. Reg. 53,381, 53,381
(Aug. 12, 2016) (to be codified at 42 C.F.R. pt. 10).
241. Id. at 53,381–82.
242. Id. at 53,382.
243. Id. The proposed 340B ADR Panel would include three members and would “ensure an unbiased
and fair review of the claims, and reduce the individual burden associated with having a single decisionmaking official who is solely responsible for reviewing and resolving claims.” Id.
244. See 563 U.S. 110, 120 (2011) (emphasizing that 340B entities’ right to proceed in court, rather
than through the formalized ADR process, could result in a “multitude of dispersed and uncoordinated
lawsuits.”).
245. The District Court for the Northern District of California dismissed the complaint. The United
States Court of Appeals for the Ninth Circuit reversed and remanded. The Supreme Court of the United
States heard the case on January 19, 2011. Astra USA, Inc v. Santa Clara Cty., Cal, 563 U.S. 110 (2011).
246. Cty. of Santa Clara v. Astra USA, Inc., No. C 05-03740 WHA, 2006 WL 1344572, (N.D. Cal.
May 17, 2006).
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Appeals for the Ninth Circuit reversed and remanded.247 The Supreme Court
granted certiorari.248 In an opinion authored by Justice Ginsburg, the Court held
that 340B entities may not enforce ceiling-price contracts between drug
manufacturers and HHS.249
Santa Clara County, operator of several 340B entities, alleged that drug
manufacturers were overcharging 340B health care facilities in violation of the
PPAs.250 Despite conceding that Congress authorized no private right of action
under § 340B for entities claiming to be overcharged, Santa Clara argued that the
340B entities and the counties that fund them are the intended beneficiaries of
the PPAs.251 Thus, Santa Clara sought compensatory damages for the drug
manufacturers’ breach of contract.252
The Court determined that PPAs “simply incorporate statutory obligations
and record the manufacturers’ agreement to abide by them.”253 The agreements
contain no negotiable terms and like the MDRP, the agreements simply serve as
the means to opt into the statutory scheme.254 The Ninth Circuit had determined
that by allowing covered entities to sue as intended beneficiaries of the PPA
would spread the burden of enforcement instead of placing it entirely on the
government.255 The Supreme Court disagreed. The Court deemed that Congress
intended for “centralized enforcement” from the government.256 Otherwise, the
absence of a private right of action would be rendered meaningless.257 The Court
held suits by 340B entities would undermine the agency’s efforts to administer
both MDRP and 340B.258
C. Orphan Drugs
i. Background
As an amendment to the Federal Food, Drug, and Cosmetic Act, the Orphan
Drug Act (ODA) was passed in 1983 “to facilitate the development of drugs for

247. Cty. of Santa Clara v. Astra USA, Inc., 588 F. 3d 1237, 1252 (9th Cir. 2009).
248. Astra USA, Inc. v. Santa Clara Cty., Cal. 563 U.S. 110 (2011).
249. Id. at 113.
250. Id. at 116.
251. See id. at 116–17 (“Congress vested authority to oversee compliance with the 340B Program in
HHS and assigned no auxiliary enforcement role to covered entities.”).
252. Id. at 116.
253. Id. at 118.
254. Id.
255. Cty. of Santa Clara v. Astra USA, Inc., 588 F.3d 1251 (9th Cir. 2009).
256. Astra, 566 U.S. at 119.
257. Id. at 118.
258. Id. at 120. The Court further notes that “the Ninth Circuit focused on the 340B Program in
isolation[.] [I]t failed to recognize that the interests of States under the Medicaid Drug Rebate Program
and covered entities under the 340B Program may conflict.” Id. at 120 n.6.
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rare diseases and conditions.”259 A rare disease or condition, or “orphan” disease,
is defined as any disease or condition which affects less than 200,000 persons in
the United States or affects more than 200,000 in the United States and for which
there is no reasonable expectation that the cost of developing and making
available a drug for such disease or condition will be recovered from sales.260
Drugs used to treat orphan diseases are, to no surprise, referred to as “orphan”
drugs.
Congress passed the ODA after concluding that “because so few individuals
are affected by any one rare disease or condition, a pharmaceutical company
which develops an orphan drug may reasonably expect the drug to generate
relatively small sales in comparison to the cost of developing the drug and
consequently to incur a financial loss.”261 To encourage the development of
orphan drugs, the ODA provides incentives to drug manufacturers. These
incentives include a seven-year market exclusivity period for the orphan drug—
as opposed to a two-year period for regular drugs; a clinical tax credit for any
expenses incurred in developing an orphan drug; research grants for clinical
testing; and an exemption from new drug application fees.262
To become an orphan drug, a drug must qualify for an orphan
designation.263 To qualify, both the drug and the disease or condition must meet
specified criteria in the ODA and FDA’s implementing regulations.264 The Food
and Drug Administration (FDA) oversees the designation and approval of orphan
drugs. Specifically, the Office of Orphan Products Development (OOPD)
“evaluates scientific and clinical data submissions from sponsors to identify and
designate products as promising for rare diseases.”265 Both the FDA and HRSA
reside under HHS.
Although a drug may be designated as an orphan drug to treat a rare disease
or condition, the drug may also be approved and used to treat multiple conditions,
including non-orphan. For example, the drug Prozac (Fluoxetine) has an orphan
designation to treat “autism and body dysmorphic disorder in children and
adolescents, but is commonly prescribed for depression, a non-orphan
259. Orphan Drug Act, Pub. L. No. 97-414, § 1(b)(4), 96 Stat. 2049, 2049 (1983) (codified as amended
at 21 U.S.C. § 360aa (2012)); PhRMA I, 43 F. Supp. 3d 28, 31 (D.D.C. 2014).
260. 21 U.S.C. § 360bb(a)(2).
261. § 1(b)(4), 96 Stat. at 2049.
262. 21 U.S.C. § 360cc(a); 26 U.S.C. § 45C (2012); 21 U.S.C. § 360ee; 21 U.S.C. § 379h(a)(1)(F);
PhRMA I, 43 F. Supp. 3d at 31.
263. 21 C.F.R. §§ 316.20–316.21 (2018). The ODA provides for the granting of an orphan designation
upon the request of a sponsor. Id. § 316.20. A sponsor seeking orphan designation for a drug must submit
a request for designation to the Office of Orphan Products Development (OOPD) with the information
required in 21 C.F.R. §§ 316.20–316.21.
264. 21 C.F.R § 316.20.
265. Developing Products for Rare Diseases and Conditions, FDA,
https://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/ucm2005525.html (last
updated Oct. 5, 2018).
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condition.”266 In addition, a drug may have an orphan designation and be
approved to treat a different disease or condition—although drugs may be
developed exclusively for orphan designation.267
In 2010, HCERA, excluded orphan drugs from 340B pricing applicable to
the newly added hospitals which include critical access hospitals, rural referral
centers, sole community hospitals, and free-standing cancer hospitals.
Subsection 340B(e), entitled “Exclusion of Orphan Drugs for Certain Covered
Entities,” provided that “[f]or covered entities described in subparagraph (M),
(N), or (O) of subsection (a)(4), the term ‘covered outpatient drug’ shall not
include a drug designated by the Secretary under section 526 of the Federal Food,
Drug, and Cosmetic Act for a rare disease or condition.”268 However, covered
entities and drug manufacturers debated the meaning of the phrase “a drug
designated . . . for a rare disease or condition.”269 Covered entities contended the
meaning of the phrase was unclear, while drug manufacturers contended that all
orphan-designated drugs, whatever their use, “were intended to be excluded from
the 340B Program for the newly added covered entities.”270
In May 2011, HRSA issued a notice of proposed rulemaking concerning
the orphan drug exclusion provision.271 “The purpose of issuing this proposed
rule is to clarify HHS’s stated effort in: (1) providing clarity in the marketplace;
(2) maintaining the 340B savings and interests to the newly-eligible covered
entities; and (3) protecting the financial incentives for manufacturing orphan
drugs designated for a rare disease or condition as indicated in the Affordable
Care Act as intended by Congress.”272 In July 2013, HRSA issued a Final Rule
interpreting section 340B(e).273
Under the Final Rule, HRSA indicated that “a covered outpatient drug does
not include orphan drugs that are transferred, prescribed, sold, or otherwise used
for the rare condition or disease for which that orphan drug was designated under
section 526 of the [Federal Food, Drug, and Cosmetics Act].”274 However, a
covered outpatient drug includes “drugs that are designated under section 526
of the FFDCA when they are transferred, prescribed, sold, or otherwise used for
any medically-accepted indication other than treating the rare disease or
condition for which the drug was designated under section 526 of the

266. PhRMA I, 43 F. Supp. 3d at 30.
267. 21 C.F.R § 316.23(b) (2018); PhRMA II, 138 F. Supp. 3d 31, 34 (D.D.C. 2015).
268. 42 U.S.C. § 256b(e) (2012)).
269. PhRMA II, 138 F. Supp. 3d at 36.
270. Id.
271. Exclusion of Orphan Drugs for Certain Covered Entities Under 340B Program, 76 Fed. Reg.
29,183 (May 20, 2011) (to be codified at 42 C.F.R. pt. 10).
272. Id. at 29,184.
273. PhRMA I, 43 F. Supp. 3d 28, 32 (D.D.C. 2014); 42 C.F.R. § 10.21 (2013).
274. PhRMA I, 43 F. Supp. 3d at 32 (quoting 42 C.F.R. § 10.21).
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FFDCA.”275 In essence, when the newly-added covered entities purchased
orphan drugs for their intended orphan use, the 340B price did not apply; yet
when the newly-added covered entities purchased orphan drugs for a non-orphan
use, the 340B price did apply.276 Drug manufacturers took issue with this
interpretation and the Pharmaceutical Research and Manufacturers of America
(PhRMA) challenged HRSA’s Final Rule in court.277
a. PhRMA I
In Pharm. Research & Manufacturers of Am. v. United States Dep’t of
Health & Human Servs. (PhRMA I), the issue was whether the newly-added
covered entities must pay full price for orphan drugs when used for a non-orphan
indication.278 Under HRSA’s Final Rule, section 340B(e) excludes orphan drugs
only when they are used for the rare disease or condition for which they received
an orphan designation. PhRMA argued (1) that the Final Rule “contravened the
plain language of the statute,” and was “therefore invalid,” and (2) that HRSA
lacked the authority to promulgate rules interpreting the orphan drug
exclusion.279 HRSA argued (1) the statute is silent as to whether the orphan drugs
exclusion applies to orphan drugs used for nonrare indications, and (2) HRSA
was authorized by statute to “promulgate regulations to establish and implement
an administrative process for the resolution of claims by covered entities that
they have been overcharged for drugs purchased” under 42 U.S.C. section
256b(d)(3)(A).280
The court noted that under the Administrative Procedure Act (APA), a
reviewing court “shall hold unlawful and set aside agency action, findings, and
conclusions found to be in excess of statutory jurisdiction, authority, or
limitations, or short of statutory right.”281 Furthermore, the court explained that
“[i]t is axiomatic that an administrative agency’s power to promulgate legislative
regulations is limited to the authority delegated by Congress.”282
The court used Chevron deference to determine whether HHS had the
authority to promulgate the Final Rule—the orphan drug rule.283 Under the
Chevron two-step process, a court will first “question whether Congress has

275. 42 C.F.R. § 10.21.
276. PhRMA I, 43 F. Supp. 3d at 32.
277. Id. at 33.
278. Id. at 32.
279. Id. at 33, 37.
280. Id. at 40–41.
281. Id. at 35 (citing 5 U.S.C. § 706(2)(c) (2012)).
282. Id. at 35 (Bowen v. Georgetown Univ. Hosp., 488 U.S. 204, 208 (1988)).
283. See Chevron U.S.A., Inc. v. Nat. Def. Council, Inc. 467 U.S. 837 (1984) (establishing the
Chevron deference principle, which requires courts to defer to agency interpretations of statutes when
presiding over administrative law disputes).
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directly spoken to the precise question at issue.”284 The court noted that “‘[i]f the
intent of Congress is clear, that is the end of the matter; for the court, as well as
the agency, must give effect to the unambiguously expressed intent of
Congress.’”285 If Congress has not directly addressed the question at issue, then
“‘the court does not simply impose its own construction on the statute, as would
be necessary in the absence of an administrative interpretation.’”286 Second,
“‘[i]f the statute is silent or ambiguous with respect to the specific issue, the
question for the court is whether the agency’s answer is based on a permissible
construction of the statute.’”287 The court again noted that “‘a court may not
substitute its own construction of a statutory provision for a reasonable
interpretation made by the administrator of an agency.’”288
The court found that the statutory provisions HHS relied upon “are specific
grants of authority that do not authorize the orphan drug rule.”289 Therefore, the
court gave “‘effect to the unambiguously expressed intent of Congress,’” and
vacated the final rule under Chevron step one.290 The court found that HHS has
acted beyond “‘the bounds of its statutory authority.’”291
In the alternative, HHS asked the court to “uphold the rule as an interpretive
rule, as opposed to a legislative rule,” under an interpretive rule theory.292 The
court was skeptical that the Final Rule—promulgated through notice comment
rulemaking and purported to have a binding legal effect—could be classified as
an interpretive rule.293 After noting HHS’s argument was “half-hearted,” the
court concluded the rule was legislative because “the rule (1) underwent notice
and comment rulemaking—the hallmark of a legislative rule—and (2) it has a
‘legal effect’ on the parties so regulated because the interpretation of ‘covered
outpatient drug,’ as well as the compliance procedures impose obligations on
covered entities and manufacturers alike.”294
The court held that Congress “specifically authorized rulemaking in three
places: (1) the establishment of an administrative dispute resolution process, (2)
284. PhRMA I, 43 F. Supp. 3d. at 35 (citing Chevron, 467 U.S. at 842–43).
285. Id. (quoting Chevron, 467 U.S at 842–43).
286. Id. (quoting Chevron, 467 U.S at 843).
287. Id. at 36 (quoting Chevron, 467 U.S at 844).
288. Id. at 36 (quoting Chevron, 467 U.S. at 844).
289. Id. at 39. (“Specifically, HHS relied upon: (1) Section 340B of the PHSA, 42 U.S.C. § 256b, as
amended, (2) Section 215 of the PHSA, 42 U.S.C. § 216, as amended, (3) Section 526 of the FFDCA, 21
U.S.C. § 360bb, as amended, (4) Section 701(a) of the FFDCA, 21 U.S.C. § 371(a); and (5) Section 1927
of the Social Security Act, 42 U.S.C. § 1396r–8, as amended. See 78 Fed. Reg. at 44027.”) (explaining
that although HHS relied upon several statutory authorizations, none appropriately grant the agency the
authority to promulgate the orphan drug rule).
290. PhRMA I, 43 F. Supp. at 39–40 (quoting City of Arlington v. FCC, 569 U.S. 290, 296 (2013)).
291. Id. at 40 (quoting City of Arlington, 569 U.S. at 297).
292. Id. at 45.
293. Id. at 46.
294. Id.
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the ‘regulatory issuance’ of precisely defined standards of methodology for
calculation of ceiling prices, and (3) the imposition of monetary civil
sanctions.”295 The court explained that the “rulemaking authority granted HHS
by Congress under the 340B program has thus been specifically limited, and HHS
has not been granted broad rulemaking authority to carry out all the provisions
of the 340B program.”296 Additionally, the court noted, “Congress has limited
HHS’s rulemaking authority to creating a system for resolving disputes between
covered entities and manufacturers—not to engaging in prophylactic nonadjudicatory rulemaking regarding the 340B program altogether.”297
The court held that Congress did not delegate broad rulemaking authority
in HRSA despite vesting the agency with the obligation to oversee and
implement the 340B Program. For the newly-added covered entities, the term
“covered outpatient drug” did not include a drug designated by the Secretary
under section 526 of the Federal Food, Drug, and Cosmetic Act for a rare disease
or condition. Therefore, drug manufacturers were not required to provide these
entities orphan drugs at 340B prices. Although a manufacturer may, at its sole
discretion, offer discounts on orphan drugs to these hospitals.
Despite the court’s ruling, HRSA maintained the decision did not invalidate
HHS’s interpretation of the orphan drug exclusion in the Rule.298 In response,
HHS issued an interpretive rule identical in substance to the vacated Final Rule
in July 2014.299 Again, PhRMA challenged HHS contending that the interpretive
rule contravened section 340B’s plain language.300
b. PhRMA II
In October 2014, PhRMA filed suit against HHS and its interpretive rule.
HRSA argued (1) “the Interpretive Rule does not constitute a final agency action
and, therefore, is not subject to judicial review”; and (2) that, “even if the rule
constitutes a final agency action, its interpretation is entitled to Skidmore
deference.”301 PhRMA argued that the Interpretive Rule was a final agency
action and that the rule conflicts with the plain language of section 340B(e).302
Ultimately, the court concluded that the Interpretive Rule was a final agency

295. Id. at 41.
296. Id. at 42 (emphasis added).
297. Id. at 42–43.
298. Availability of Interpretive Rule: Implementation of the Exclusion of Orphan Drugs for Certain
Covered Entities Under the 340B Program, 79 Fed. Reg. 42,801, 42,801 (July 23, 2014).
299. PhRMA I, 138 F. Supp. 3d at 32; Availability of Interpretive Rule: Implementation of the
Exclusion of Orphan Drugs for Certain Covered Entities Under the 340B Program, 79 Fed. Reg. at 42,801.
300. PhRMA II, 138 F. Supp. 3d 31, 32 (D.D.C. 2015).
301. Id. at 38.
302. Id.
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action and that the Interpretive Rule contravened the plain language of section
340B(e).303
HHS maintained that “‘interpreting the statutory language to exclude all
indications for a drug that has an orphan drug designation would be contrary to
the Congressional intent of section 340B(e) to balance the interests of orphan
drug development and the expansion of the 340B Program to new entities.’” 304
For the same reasoning, HHS determined section 340B(e) to “‘not exclude drugs
that are transferred, prescribed, sold, or otherwise used for conditions or diseases
other than for which the drug was designated.’”305
Following the Interpretive Rule, HRSA sent letters to drug manufacturers
informing them that covered entities were denied 340B discounts on products
with an orphan designation.306 HRSA informed the drug manufacturers of its
interpretation of the statute—340B(e)—and stated that manufacturers are “‘out
of compliance with statutory requirements as described in HRSA’s interpretive
rule.’”307 HRSA cautioned that “‘[m]anufacturers that do not offer the 340B price
for drugs with an orphan designation when those drugs are used for an indication
other than the rare condition or disease for which the drug was designated . . .
are violating section 340B(a)(1) of the PHSA and the terms of their
Pharmaceutical Pricing Agreement.’”308 HRSA noted that drug manufacturers
were required to “‘refund covered entities charged more than the statutory ceiling
price for covered outpatient drugs” and requested the manufacturers to “respond
within 30 days to notify HRSA of your plan to repay affected covered entities
and to institute the offer of the discounted price in the future.’”309 On its website,
HRSA also stated that “‘failure to comply with the statutory requirements could
subject a manufacturer or covered entity to an enforcement action’” which
included termination of a PPA.310
The court noted that PhRMA did not directly challenge HHS’s authority to
issue an Interpretive Rule.311 The court conceded that HHS had the authority to
advise the public of its interpretation of the statute.312 Accordingly, despite fact
that the court had previously concluded that HHS lacked the authority to
promulgate the rule as a binding statement of law, the court acknowledged HHS
was “not forbidden altogether from proffering its interpretation of the statute.”313
303.
304.
305.
306.
307.
308.
309.
310.
311.
312.
313.

Id. at 33.
Id. at 37 (citation omitted).
Id. (citation omitted).
Id. (citation omitted).
Id. (citation omitted) (emphasis in original).
Id. (citation omitted) (emphasis in original).
Id. (citation omitted).
Id. at 37–38 (quoting First Am. Compl. Ex. D, ECF No.11–4).
Id. at 38–39.
Id. at 39.
Id.
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First, the court had to decide whether the Interpretive Rule was a final
agency action subject to judicial review. HHS argued that the Interpretive Rule
was not a final agency action until “HHS initiate[d] an enforcement action
against a drug manufacturer and impose[d] a penalty for not complying with the
statutory provision.”314 HHS claimed that the Interpretive Rule in itself did not
“alter the legal obligations of the program participants,” and thus, had no legal
force “independent of any binding effect that the statute itself.”315 Put
differently, HHS argued “that the statute—and not the Interpretive Rule, itself—
is binding on the parties.”316
The court conceded that interpretive rules that lack “the force of law
‘generally do not qualify’ as a final agency action.”317 However, the court
continued, “‘an agency’s other pronouncements’—beyond legislative rules—
’can, as a practical matter, have a binding effect’ which contributes to a finding
that the action is ‘final.’”318 The court found that the Interpretive Rule “represents
a definitive and purely legal determination that puts pharmaceutical
manufacturers to the painful choice of complying with HHS’s interpretation or
risking the possibility of an enforcement action at an uncertain point in the
future.”319
The court determined that, “regardless of classification, the burdens posed
by HHS’s Interpretive Rule” were “sufficiently significant to rise to the level of
a final agency action.”320 Ultimately, the court concluded that the Interpretive
Rule constituted a final agency action within the ambit of an agency action under
5 U.S.C. § 704.321
The court held that HRSA lacks the authority to promulgate a binding
statement of law.322 The court acknowledged HHS’s argument, but found that it
is, “not for [this Court] to rewrite the statute.”323 The impact of the decision is
the orphan drug interpretive rule was invalid and calls into question HRSA’s
legal authority to issue a binding guidance. The court concluded by stating
“Congress remains free to amend section 340B(e) if it determines that, in
practice, the scheme it has set up is not a workable one or does not provide the
hoped-for benefits to the extent envisioned.”324
314. Id. at 40.
315. Id. at 44.
316. Id.
317. Id. at 41 (quoting Am. Tort Reform Ass’n v. Occupational Safety & Health Admin., 738 F.3d
387, 395 (D.C. Cir. 2013)).
318. Id. at 41 (quoting Appalachian Power Co. v. EPA, 208 F.3d 1015, 1021–22 (D.C. Cir. 2000)).
319. Id. at 43.
320. Id. at 46–47.
321. Id. at 47.
322. Id. at 39.
323. Id. at 53.
324. Id.
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c. Orphan Drugs Post-PhRMA
After PhRMA II, “[f]or rural referral centers, sole community hospitals,
critical access hospitals, and free-standing cancer hospitals participating in the
340B Program, the term ‘covered outpatient drug’ does not include a drug
designated by the Secretary under section 526 of the Federal Food, Drug, and
Cosmetic Act for a rare disease or condition.”325 Therefore, drug “manufacturers
are not required to provide these covered entities orphan drugs under the 340B
Program.”326 Although “[a] manufacturer may, at its sole discretion, offer
discounts on orphan drugs to these hospitals.”327
D. The Mega-Reg and Mega-Guidance Withdrawals
In 2014, HRSA intended to issue comprehensive regulations in an effort to
provide better clarity and guidance for both covered entities and drug
manufacturers.328 Nicknamed the “Mega-Reg” or “Mega-Regs,” these
regulations were expected to cover the 340B definition of a patient, compliance
requirements for contract pharmacy arrangements, hospital eligibility
requirements, and eligibility of hospital offsite facilities.329 However, the
decision in PhRMA I called into question HRSA’s ability to issue binding
legislative regulations for 340B and forced HRSA to retract the guidance in
November 2014.330 In its place, HRSA published proposed Omnibus Guidance
in the Federal Register on August 28, 2015.331
Intended to replace the Mega-Reg, the Omnibus Guidance—often called
“MegaGuidance”—would have included several significant updates to the 340B
Program.332 Some of the key issues the proposed guidance addressed included
the definition of an eligible patient, DSH and child sites333 eligibility, and
contract pharmacy arrangements.334 The redefining of patient eligibility would
have likely limited the program’s scope. However, on January 30, 2017, the
325. 340B Drug Pricing Program, Orphan Drugs, HEALTH RES. & SERVS. ADMIN.,
https://www.hrsa.gov/opa/program-requirements/orphan-drug-exclusion/ (last updated June 2018).
326. Id.
327. Id.
328. Kara Stencel, The 340B Drug Discount Program, HEALTH AFF. (Nov. 17, 2014),
https://www.healthaffairs.org/do/10.1377/hpb20141117.14335/full/healthpolicybrief_130.pdf/.
329. Id.
330. Id.
331. 340B Drug Pricing Program Omnibus Guidance, 80 Fed. Reg. 52,300, 52,300–02, 52,306 (Aug.
28, 2015).
332. Todd A. Nova et al., 340B “Mega-Guidance” Withdrawn – Next Steps Unclear, HALL RENDER:
HEALTH L. NEWS (Feb. 1, 2017), http://www.hallrender.com/2017/02/01/340b-mega-guidancewithdrawn-next-steps-unclear/.
333. 340B Drug Pricing Program Omnibus Guidance, 80 Fed. Reg. at 52,301. Child sites are eligible
outpatient facilities which may include offsite clinics, departments, or services that are an integral part of
the 340B hospital. Id.
334. Id. at 52,301–03.
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340B Mega-Guidance was withdrawn 10 days following the Trump
administration directed agencies to temporarily postpone the effective date of
regulations that had been published in the Federal Register but had not yet taken
effect.335
IV. RETHINKING 340B
The growth of the 340B Program shows no signs of slowing down. HRSA’s
anticipated release of the Mega-Guidance would have likely limited the scope of
the program. However, as discussed, HRSA withdrew the Guidance in January
2017—suffering the same fate as the MegaReg. Still, the 340B Program is
anticipated to keep growing at a rapid pace. Contributing to the growth is the
expansion of practice acquisition, physician practice affiliations, patient
referrals, and contract pharmacies. In 2015, over 390 hospitals enrolled in the
program for the first time—a trend that is expected to continue for the next two
to three years.336 In 2016, over 68 percent of hospitals have at least one contract
pharmacy—up from 13 percent from March 2010.337
Presently, drug manufacturers and qualifying health care providers seems
to be locked in a zero-sum game. While manufacturers desire changes to the
program, qualifying providers want the program protected. Manufacturers seek
to narrow the scope of the program and desire for a more direct link in between
drug discounts and indigent patient care. In contrast, 340B providers prefer the
program’s current form—albeit hospitals would likely appreciate clarity in
certain areas—and desire the continuation in the ability to use revenue generated
from the discounts without restrictions.
At the beginning of this paper, I pointed out that the 340B Program is
designed to help uninsured, indigent patients by giving qualifying health care
facilities access to discounts for outpatient drugs. Specifically, covered entities
would be granted access to the discounts to enable the entities “to stretch scarce
Federal resources as far as possible, reaching more eligible patients and
providing more comprehensive services.”338 Although hospitals are benefiting
financially from the program, it may be inconsistent with the design of the
program.
The issue seems not to be that hospitals are generating revenue from the
340B Program, rather critics contend that covered entities are exploiting the
program to generate revenue at the expense of drug manufacturers and patients.
However, drug manufacturers cannot play the role of a helpless victim.
335. Memorandum for the Heads of Executive Departments and Agencies; Regulatory Freeze Pending
Review, 82 Fed. Reg. 8346, 8346 (Jan. 24, 2017).
336. AARON VANDERVELDE & ELEANOR BLALOCK, 340B PROGRAM SALES FORECAST: 2016-2021 4
(2016), http://340breform.org/userfiles/December%202016%20BRG%20Growth%20Study.pdf.
337. Id.
338. H.R. REP. NO. 102-384, pt. 2, at 12 (1992).
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Manufacturers have found loopholes in the program as well. For example, given
the orphan drug ruling, drug manufacturers have huge incentives to exclude all
specialty drugs, often biologics, and other high-cost drugs including oncology
drugs from the 340B Program. Manufacturers exploit the program by claiming
orphan status and then market the drug for more common conditions.
As drug manufacturers and covered entities attempt to out-strategize one
another, the patient is the one who ends up suffering. Although patients benefit
from the program as covered entities provide additional services and
uncompensated care, indigent patients are harmed by significant increases in the
cost of medications or insurance premiums. However, given the inelastic demand
of health care, one has to assume that patients would not prefer the increase, but
are willing to accept the tradeoff for services that may be lifesaving.
Despite the fundamental challenges plaguing the 340B Program, it may also
face an existential challenge with the Trump administration. President Donald
Trump campaigned on repealing and replacing the ACA. Although a full repeal
is unlikely, the 340B Program could be affected indirectly under a partial repeal.
As discussed, the ACA made several notable changes to the 340B Program. A
repeal of the ACA would possibly impact the eligibility of qualifying children’s
hospitals, critical access hospitals, free standing cancer hospitals, sole
community hospitals, and rural referral centers—stripping these entities of 340B
eligibility. The ACA also expanded Medicaid, although, under Sebelius,339 the
Supreme Court held states could opt out of the expansion. More Medicaid
patients means more hospitals would qualify for the 340B Program. However,
block grants for Medicaid would likely have an impact on 340B. The ACA also
added language excluding orphan drugs from 340B discounts leading to PhRMA
I and PhRMA II. A full or partial repeal could potentially mean orphan drugs
would fall under outpatient covered drugs eligible for 340B pricing. Lastly, the
Trump administration has raised concerns about the rise in the cost of drugs.
Congress may be inclined to target programs such as 340B as a way to reform
drug price regulation. Generally, a change in administration can create
uncertainty, but only time will tell.
The 340B Program faces several internal challenges due to its nuanced and
cumbersome nature. Rarely is there a simple solution for a complex problem.
However, updating a few areas of the program would have a huge impact. First
and foremost, Congress must grant HRSA more oversight. Second, the program
needs an updated definition of patient. Third, contract pharmacies require more
attention. Fourth, an increase in auditing will help curve drug diversion and
duplicate discounts. And finally, greater transparency should be mandated to
ensure the program is being used to help indigent patients.

339. See Nat’l Fed’n of Indep. Bus. v. Sebelius, 567 U.S. 519, 585 (2012) (holding that the states could
opt out of the expansion).
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A. Congressional Action Is Needed for Greater Oversight
The holdings in PhRMA I and PhRMA II are problematic for HRSA and the
340B Program. The ruling in PhRMA I held that Congress had only granted
HRSA authority to issue legislative rules regarding the 340B program in three
very limited circumstances.340 Thus, HRSA does not have “broad rulemaking
authority to carry out all the provisions of the 340B program.”341 In PhRMA II,
the court held that HRSA lacks the authority to promulgate a binding statement
of law.342 The ruling calls into question HRSA’s legal authority to issue a binding
guidance and leaves HRSA’s authority to administer the 340B Program on shaky
grounds. PhRMA’s success in litigation has provided a blueprint and precedent
for future challenges when a guidance runs contrary manufacturers’ interests.
Statutory authority is a requirement for HRSA to properly implement the
program. HRSA takes much criticism for the 340B Program’s shortcomings.
However, as confirmed by PhRMA I, HRSA lacks the general rulemaking
authority needed to resolve many issues facing the 340B Program. Congress
vested HRSA with the responsibility to administer the program, but failed to give
HRSA the authority to enforce the program. Thus, congressional action is
required. As the court held in PhRMA II, “Congress remains free to amend
section 340B(e) if it determines that, in practice, the scheme it has set up is not a
workable one or does not provide the hoped-for benefits to the extent
envisioned.”343 Agency guidance no matter how significant, is insufficient to fix
340B.
B. HRSA Must Update the Definition of Patient
Ambiguity in the definition of patient is problematic. The current definition
of patient eligibility comes from a guidance released in 1996—prior to contract
pharmacies and the ACA. In the now defunct Mega-Guidance, HRSA proposed
an updated definition to “address the diverse set of 340B covered entities.”344
However, given the Mega-Guidance suffered the same fate as the Mega-Reg, it
is unlikely that this definition will come to fruition. Until HRSA issues a final
guidance, for the foreseeable future, the same issues will remain.

340. See PhRMA I, 43 F. Supp. 3d 28, 41 (D.D.C. 2014) (holding that Congress had only granted
HRSA authority to issue legislative rules regarding the 340B program while establishing an administrative
dispute resolution process, regulating the precise standards for calculating 340B ceiling prices, and
imposing monetary civil sanctions).
341. Id. at 42.
342. See PhRMA II, 138 F. Supp. 3d 31, 39 (D.D.C. 2015) (holding that HHS lacks the authority to
promulgate the rule as a binding statement of law; HHS is not forbidden altogether from proffering its
interpretation of the statute).
343. Id. at 53.
344. 340B Drug Pricing Program Omnibus Guidance, 80 Fed. Reg. 52,300, 52,306 (Aug. 28, 2015).
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As noted by the GAO, the lack of specificity for who is an eligible patient
leads to covered entities interpreting the term either too broadly or too narrowly.
Currently, covered entities are incentivized to favor a broader, more liberal
definition of patient in order to obtain 340B discounts on drugs. The definition
allows anyone, regardless of wealth or insurance, to qualify for 340B discounted
drugs. Essentially, all patients qualify so long as the covered entity qualifies for
the program. Remember, the revenue generated is not restricted by the 340B
statute.
To reiterate, an individual is a “patient” of a hospital if: (1) “the covered
entity has established a relationship with the individual, such that the covered
entity maintains records of the individual’s health care;” and (2) “the individual
receives health care services from a health care professional who is either
employed by the covered entity or provides health care under contractual or other
arrangements—e.g. referral for consultation—such that responsibility for the
care provided remains with the covered entity.”345 Simply put, the definition of
a patient requires that the hospital maintains records of the individual’s health
care and receives care by a professional affiliated with the hospital.346 With
advances in technology, maintaining records of the individual’s health care is
hollow and sets a low bar. Digital records can be maintained on or off-site and
accessed by any care provider or third-parties that are given access. Furthermore,
“other arrangements” has not been defined. Thus, the lack in specificity leads to
questionable “arrangements” including providers who use the entity for
administrative functions rather than actually having a responsibility for care.347
It can be argued that Congress intentionally created a broad program which
would allow for covered entities to take advantage of the drug discount without
regard to the patient’s income or insurance. Others may argue that the Congress’s
intent was clear and that the intention of the 340B Program is to pass the drug
discounts directly to indigent patients. However, a clear definition should benefit
both drug manufacturers and covered entities. For drug manufacturers, an
updated definition should cut down on drug diversion. For covered entities, an
updated definition would enable an entity to ensure program compliance.
The current definition only exacerbates the issues with the 340B Program.
The definition is not only fundamentally flawed through lack of specificity, it is
antiquated. If an entity interprets the definition too broadly, then it may lead to
unintended diversion. However, if an entity interprets the definition too
narrowly, then it may lead to entities limiting the benefit of the 340B Program in
fear of noncompliance. Moreover, the definition does not account for the
345. Notice Regarding Section 602 of the Veterans Health Care Act of 1992 Patient and Entity
Eligibility, 61 Fed. Reg. 55,156, 55,157–58 (Oct. 24, 1996).
346. Id.
347. See GAO, DRUG PRICING, supra note 9, at 23 (explaining the confusion surrounding and need
for clarification of the definition of “other arrangements”).
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complex organizational structures of hospitals or account for the convoluted
contracting arrangements of contract pharmacies.
Under the Mega-Guidance, HRSA recommended a “prescription-byprescription or order-by-order basis” rather than the broad application, and
discussed additional criteria for eligibility.348 However, the additional criteria
would only alleviate some issues with the definition. One option is for the
definition to allow the discount to be available only for indigent patients of a
covered entity. Another option is to require multiple interactions or visits to
ensure the patient is really a patient of the covered entity. Still, another option is
to require a physician to write a prescription at the time the patient is at a
qualifying entity in order to ensure billing.
Regardless of what HRSA chooses to implement, an updated guidance
regarding patient eligibility is necessary. The definition of patient is such an
integral part of the 340B Program. Despite repeated calls and failed attempts to
update the definition, however, the 1996 definition remains. Without a clear
definition, interpretations will continue to vary and compliance is at risk. HRSA
will likely issue a formal guidance addressing the issue at some point in the
future, until then, the 1996 patient definition remains in effect.
C. Contract Pharmacies
The use of contract pharmacies represents a dramatic growth in the 340B
Program. The 2010 guidance allowed all covered entities to contract with
multiple outside pharmacies.349 Between March 2010 and May 2013, the number
of unique pharmacies serving as 340B contract pharmacies grew by 770 percent,
and the total number of contract pharmacy arrangements grew by 1,245
percent.350 In 2016, over 68 percent of hospitals had at least one contract
pharmacy.351
Contract pharmacy arrangements are beneficial for multiple reasons
including allowing patients to fill prescriptions somewhere other than the
covered entity. However, the increased use of contract pharmacies may result in
greater risk of drug diversion.352 Likewise, contract pharmacies may result in a
greater risk for duplicate discounts given the complexity of the arrangements.353
348. 340B Drug Pricing Program Omnibus Guidance, 80 Fed. Reg. 52,300, 52,319 (Aug. 28, 2015).
349. Notice Regarding 340B Drug Pricing Program–Contract Pharmacy Services, 75 Fed. Reg.
10,272, 10,273 (Mar. 5, 2010).
350. Wakefield, supra note 81, at 2.
351. AARON VANDERVELDE & ELEANOR BLALOCK, 340B PROGRAM SALES FORECAST: 2016-2021 4
(2016), http://340breform.org/userfiles/December%202016%20BRG%20Growth%20Study.pdf.
352. See GAO, DRUG PRICING, supra note 9, at 28 (explaining why contract pharmacies, as opposed
to in-house pharmacies, increases the likelihood of drug diversion).
353. See SUZANNE MURRIN, OFFICE OF INSPECTOR GENERAL, HEALTH & HUM. SERVS., STATE
EFFORTS TO EXCLUDE 340B DRUGS FROM MEDICAID MANAGED CARE REBATES, 1, 6, 14, 15 (2016),
https://oig.hhs.gov/oei/reports/oei-05-14-00430.pdf (discussing how the structure of many contract
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Although the duplicate discount prohibition applies to contract pharmacies,
sophisticated inventory tracking systems and third-party administrators (TPAs)
are costly and may require greater effort and involvement.
Covered entities that establish a contract pharmacy are required to oversee
these arrangements to prevent diversion of 340B drugs and duplicate discounts
through Medicaid.354 In 2014, HHS Office of Inspector General (OIG) conducted
an audit of the 340B Program and reported that many contract pharmacy
arrangements created complications in preventing diversion and duplicate
discounts.355 The report found that most covered entities in the study did not
conduct recommended oversight and only a few entities reported retaining
independent auditors, which was also recommended.356
Covered entities should not dispense 340B-purchased drugs to Medicaid
patients through their contract pharmacies, unless they have an arrangement to
prevent duplicate discounts.357 In order for states to collect rebates and avoid
duplicate discounts, 340B drug claims must be identified and excluded. The OIG
report found that covered entities use different methods to identify 340B-eligible
prescriptions in order to prevent diversion.358 The inconsistency results in similar
types of prescriptions categorized in different ways.359 The inconsistency leads
to greater diversion, causing states to forego proper drug rebates, through the
MDRP, and manufacturers to sell a drug at 340B prices while paying a Medicaid
rebate. As a result, manufacturers pay too much in rebates under duplicate
discounts and States pay too much for drugs under missed rebates.
In 2016, the OIG recommended the use of claim-level methods to
accurately identify 340B claims and prevent duplicate discounts. To prevent
duplicate discounts, HRSA should follow the OIG’s recommendation and
instruct contract pharmacies to regularly submit reports that identify 340B claims
to the states. States can then remove all 340B claims and prevent duplicate
discounts. Another option is to require covered entities to avoid dispensing 340B

pharmacy arrangements creates technical challenges regarding 340B applications leading to duplicate
discounts).
354. See Notice Regarding 340B Drug Pricing Program—Contract Pharmacy Services, 75 Fed. Reg.
10,272, 10,273–78 (Mar. 5, 2010) (responding to comments questioning the duty of covered entities to
prevent 340B drug diversion and outlining possible strategies for covered entities to monitor contract
pharmacy arrangements).
355. Wakefield, supra note 81, at 16.
356. See id. at 2, 7, 14, 15 (reporting that few covered entities in study of 30 complete oversight
activities recommended by HRSA, and only 7 of 30 covered entities in study had reported using an auditor
for contract pharmacy arrangements).
357. 340B Drug Pricing Program—Contract Pharmacy Services, 75 Fed. Reg. at 10,278.
358. Wakefield, supra note 81, at 9.
359. See generally Wakefield, supra note 81 (reporting that covered entities in the study used different
methods to identify 340B prescriptions, resulting in some covered entities identifying a prescription as
340B eligible while other covered entities did not).
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drugs to any Medicaid beneficiaries through contract pharmacies. However, that
would limit contract pharmacies providing 340B drugs to indigent patients.
Overall, effective methods for identifying 340B claims are needed to ensure
compliance with the statutory prohibition on drug diversion and duplicate
discounts. The complexity of the contract pharmacy arrangements requires
updated guidelines to ensure uniformity. As the OIG report indicated contract
pharmacies follow different methods in identifying 340B claims. A universal
process, such as a claim-level method, would reduce the risk of diversion and
duplicate discounts.
D. Increased Audits
HRSA needs to increase auditing. All 340B covered entities are required to
ensure program integrity and maintain accurate records documenting compliance
with all 340B Program requirements. Statutorily, HRSA has the authority to
audit covered entities to ensure compliance with the 340B Program
requirements.360
Despite this ability, for nearly the first 20 years of the 340B Program,
HRSA relied heavily on self-policing. By 2011, HRSA had not conducted a
single audit.361 The GAO deemed self-policing problematic because participants
in the 340B Program had “little incentive to comply with program requirements,
because few have faced sanctions for non-compliance.”362 After the GAO
recommended that HRSA conduct selective audits of 340B covered entities,
HRSA implemented a risk-based and targeted approach to conducting audits on
covered entities in 2012.363 HRSA has continued to audit covered entities and
posts the results of each year’s audit on its website.364
Covered entities are required to permit HRSA and manufacturers to audit
records that directly pertain to compliance with the prohibition of resale/transfer
or double discounts.365 HRSA may terminate the manufacturer’s PPA if found to
be overcharging a covered entity, which would also terminate the manufacturer’s
eligibility for Medicaid coverage.366

360. See generally 42 U.S.C. § 256b(a)(5)(C) (2010) (outlining the requirements for agreements
between the Secretary and the manufacturers and suppliers of 340B drugs).
361. GAO, DRUG PRICING, supra note 9, at 25.
362. Id. at 33.
363. 340B Drug Pricing Program: Important Benefit, Significant Responsibility, HEALTH RES. AND
SERVS. ADMIN., https://www.hrsa.gov/opa/updates/update.html (last updated Apr. 2017).
364. See 42 U.S.C. § 256b(d)(2)(B)(i) (2012) (establishing that manufacturers are subject to auditing
by HRSA to ensure compliance with the 340B Program, pursuant to section 42 U.S.C. § 256b(d)(1)(B)(iiv) of the Public Health Service Act. Failure to comply with 340B pricing requirements may make the
manufacturer liable to covered entities for refunds of overpriced 340B drugs).
365. Id. § 256b(a)(5)(C).
366. Overview of the 340B Drug Pricing Program, 340B HEALTH, https://www.340bhealth.org/
members/340b-program/overview/ (last visited Oct. 28, 2018).
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Despite the increase in audits since 2012, more auditing should be
mandated. By increasing auditing, covered entities have greater incentive to
ensure compliance with 340B requirements. Drug manufacturers, who also may
audit covered entities, should increase auditing to ensure 340B requirements. In
addition, if HRSA would authorize state Medicaid programs to have access to
340B prices, then Medicaid programs can better audit for compliance with 340B
billing.
Unfortunately, auditing is complex, time consuming, and expensive. Until
2009, HRSA relied on discretionary spending to staff the OPA.367 In 2016, the
OPA operated on an annual budget of approximately $10 million.368 Moreover,
auditing may be deemed inefficient considering the flexibility of some of the
program requirements—consider the definition of patient for example.
Nevertheless, all 340B covered entities are required to ensure program integrity
and maintain accurate records documenting compliance with all 340B Program
requirements. Although HRSA has increased auditing in the last few years, much
more is required to ensure program compliance.
E. Greater Transparency
Hospitals are using the 340B Program to generate revenue. However,
exactly where that revenue is going in not always apparent. To be clear, covered
entities are under no obligation to pass on the savings to patients directly. The
340B statute does not restrict how covered entities can use revenue. Thus,
covered entities are within their right to generate revenue and “use the funds to
expand the number of patients served, increase the scope of services offered to
low-income and other patients, invest in capital, cover administrative costs, or
for any other purpose.”369
In 2013, 340B hospitals provided $28.6 billion in uncompensated care,
which was four times the amount of drugs purchased through the 340B
program.370 However, a May 2016 report from Alliance for Integrity and Reform
of 340B claimed a dramatic decline in the charity care provided by 340B
hospitals.371 The report indicated that in total, 64 percent of 340B hospitals

367. See generally Omnibus Appropriations Act of 2009, Pub. L. No. 111-8, 123 Stat. 524.
368. DEPARTMENT OF HEALTH AND HUMAN SERVICES, HEALTH RESOURCES AND SERVICES
ADMINISTRATION, JUSTIFICATION OF ESTIMATES FOR APPROPRIATIONS COMMITTEES 325 (2017),
http://www.hrsa.gov/about/budget/budgetjustification2017.pdf.
369. MEDPAC, supra note 12, at 8.
370. Examining the 340B Drug Pricing Program: Hearing Before the Subcomm. on Health of the
H. Comm. On Energy and Commerce, 114th Cong. 2 (2015) (statement of the American
Hospital Association), https://www.aha.org/sites/default/files/aha-statement-to-the-house-ec-healthsubcommittee-re-examining-the-340b-drug-pricing-program.pdf.
371. See ALLIANCE FOR INTEGRITY AND REFORM OF 340B, BENEFITING HOSPITALS, NOT PATIENTS:
AN ANALYSIS OF CHARITY CARE PROVIDED BY HOSPITALS ENROLLED IN THE 340B DISCOUNT PROGRAM
9–10
(2016),
http://340breform.org/userfiles/May%202016%20AIR340B%20Avalere%20Charity
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provided less charity care than the national average for all hospitals, including
for-profit hospitals.372 Furthermore, in more than one-third—37 percent—of
340B hospitals, charity care represented less than 1 percent of total patient
costs.373
Greater transparency should be mandated to ensure the program is being
used to help indigent patients. Mandating increased transparency in revenue
generated by a 340B covered entity will help illuminate exactly what the entity
does with the profits. Currently, HRSA does not have the statutory authority to
track how entities revenue generated from the program.374 However,
congressional action should give HRSA this authority. Transparency would
allow others to see if a covered entity is passing on any revenue to the
community, or if the covered entity is developing services to better serve the
indigent—as the program was intended.
IV. CONCLUSION
Created in 1992, the 340B Program was set up to provide “protection from
drug price increases to specified Federally-funded clinics and public hospitals
that provide direct clinical care to large numbers of uninsured Americans.”375
The program was to extend drug discounts to the most vulnerable patients, the
“medically uninsured, on marginal incomes, and have no other source to turn to
for preventive and primary care services.”376 However, after nearly two-and-a
half decades since its signing, it is unclear whether the program operates in
accordance to its statutory foundation.
This paper has highlighted the history of the 340B Program, the rapid
expansion after the ACA, and the fundamental issues plaguing the program.
Although many issues troubling the 340B Program could not have been foreseen
in 1992, the program is in desperate need of a revision. Specifically, this paper
concludes that the program needs Congressional action to grant HRSA more
oversight, an updated definition of patient, more regulation on contract
pharmacies, an increase in auditing, and greater transparency to better serve all
the parties involved.
Critics of the 340B Program argue that Congress could have ensured
covered entities would pass the savings on to patients by simply stating it. Critics
have also questioned whether covered entities even need discounts given the

%20Care%20Study.pdf (emphasizing that 64% of 340B hospitals provide charity care at rates below the
national average).
372. Id. at 9.
373. Id. at 9.
374. MEDPAC, supra note 12, at 8.
375. H.R. REP. NO. 102-384, pt. 2, at 12 (1992).
376. S. REP. NO. 102-259, at 6 (1992).
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ACA has increased health insurance coverage to more Americans.377 Despite the
critics, this paper argues that the 340B Program has helped indigent patients.
As indicated above, rarely is there a simple solution for a complex problem.
The 340B Program faces several internal challenges due to its nuanced and
cumbersome nature. However, this paper has highlighted several key areas of the
program, if updated, would have a huge impact. In the words of Ann Maxwell,
“[w]ithout clear rules, HRSA oversight is compromised, interpretations of
program rules vary, and vulnerabilities in 340B program integrity will persist.”378
Tradeoffs are inevitable. However, any substantial change to the 340B
Program should protect the original intent. Currently, competing incentives
between drug manufacturers and covered entities have turned this well-intended
program into a revenue generating arrangement. Still, the 340B Program has
enabled covered entities to increase services provided. For some patients, these
services may be the difference between life and death.

377. GAO, DRUG PRICING, supra note 9, at 4.
378. Examining the 340B Drug Pricing Program: Hearing Before the Subcomm. on Health before the
H. Comm. on Energy and Commerce: Subcomm. on Health, 114th Cong. 7–8 (2015) (testimony of Anne
Maxwell, Assistant Inspector General, Office of Inspector General).

